<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Med</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosmed</journal-id>
<journal-title-group>
<journal-title>PLOS Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1549-1277</issn>
<issn pub-type="epub">1549-1676</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pmed.1002428</article-id>
<article-id pub-id-type="publisher-id">PMEDICINE-D-17-00206</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Digestive system procedures</subject><subj-group><subject>Liver transplantation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Transplantation</subject><subj-group><subject>Organ transplantation</subject><subj-group><subject>Liver transplantation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Transplantation</subject><subj-group><subject>Organ transplantation</subject><subj-group><subject>Renal transplantation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Urinary system procedures</subject><subj-group><subject>Renal transplantation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Research design</subject><subj-group><subject>Clinical research design</subject><subj-group><subject>Adverse events</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject><subj-group><subject>Drug metabolism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject><subj-group><subject>Drug administration</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Metabolites</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial</article-title>
<alt-title alt-title-type="running-head">Generic and innovator tacrolimus product bioequivalence in transplant recipients</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4835-9197</contrib-id>
<name name-style="western">
<surname>Alloway</surname>
<given-names>Rita R.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Vinks</surname>
<given-names>Alexander A.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Fukuda</surname>
<given-names>Tsuyoshi</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8471-9826</contrib-id>
<name name-style="western">
<surname>Mizuno</surname>
<given-names>Tomoyuki</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>King</surname>
<given-names>Eileen C.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zou</surname>
<given-names>Yuanshu</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Jiang</surname>
<given-names>Wenlei</given-names>
</name>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4280-0842</contrib-id>
<name name-style="western">
<surname>Woodle</surname>
<given-names>E. Steve</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1070-9315</contrib-id>
<name name-style="western">
<surname>Tremblay</surname>
<given-names>Simon</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Klawitter</surname>
<given-names>Jelena</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6413-4820</contrib-id>
<name name-style="western">
<surname>Klawitter</surname>
<given-names>Jost</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Christians</surname>
<given-names>Uwe</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Division of Nephrology and Hypertension, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Division of Biostatistics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food &amp; Drug Administration, Silver Spring, Maryland, United States of America</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>iC42 Clinical Research and Development, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Taal</surname>
<given-names>Maarten W.</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Royal Derby Hospital, UNITED KINGDOM</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>I have read the journal's policy and the authors of this manuscript have the following competing interests: RRA serves on the following corporate advisory committees: SangStat Medical Corporation Pharmacy Advisory Board, Biogen Pharmaceutical Corporation, Anti-CD40 Ligand Scientific Advisory Board, Protein Design Labs, Abbott Pharmaceutical Corporation, Tristar Enterprises, Inc. Clinical Trials Committee, Fujisawa Clinical Pharmacy Advisory Board, Roche Clinical Pharmacy Advisory Board, Sanofi Genzyme Advisory Board and Speakers Bureau, and Veloxis Speakers Bureau, with Research Grants with Novartis and Bristol Myers Squibb. UC reports research grants with Astellas, BioRad, Biosensors, Biotronik, HepQuant, Novartis, Roche Diagnostics, Siemens Healthcare, Thermo-Fisher, Fujirebio, Veloxis, and Waters.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">Rita.Alloway@uc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>11</month>
<year>2017</year>
</pub-date>
<volume>14</volume>
<issue>11</issue>
<elocation-id>e1002428</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">
<license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">Creative Commons CC0</ext-link> public domain dedication.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pmed.1002428"/>
<related-article ext-link-type="uri" id="related001" related-article-type="companion" xlink:href="info:doi/10.1371/journal.pmed.1002429" xlink:type="simple">
<article-title>Bioequivalence of twice daily oral in transplant recipients. More evidence for consensus?</article-title>
</related-article>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>Although the generic drug approval process has a long-term successful track record, concerns remain for approval of narrow therapeutic index generic immunosuppressants, such as tacrolimus, in transplant recipients. Several professional transplant societies and publications have generated skepticism of the generic approval process. Three major areas of concern are that the pharmacokinetic properties of generic products and the innovator (that is, “brand”) product in healthy volunteers may not reflect those in transplant recipients, bioequivalence between generic and innovator may not ensure bioequivalence between generics, and high-risk patients may have specific bioequivalence concerns. Such concerns have been fueled by anecdotal observations and retrospective and uncontrolled published studies, while well-designed, controlled prospective studies testing the validity of the regulatory bioequivalence testing approach for narrow therapeutic index immunosuppressants in transplant recipients have been lacking. Thus, the present study prospectively assesses bioequivalence between innovator tacrolimus and 2 generics in individuals with a kidney or liver transplant.</p>
</sec>
<sec id="sec002">
<title>Methods and findings</title>
<p>From December 2013 through October 2014, a prospective, replicate dosing, partially blinded, randomized, 3-treatment, 6-period crossover bioequivalence study was conducted at the University of Cincinnati in individuals with a kidney (<italic>n</italic> = 35) or liver transplant (<italic>n</italic> = 36). Abbreviated New Drug Applications (ANDA) data that included manufacturing and healthy individual pharmacokinetic data for all generics were evaluated to select the 2 most disparate generics from innovator, and these were named Generic Hi and Generic Lo. During the 8-week study period, pharmacokinetic studies assessed the bioequivalence of Generic Hi and Generic Lo with the Innovator tacrolimus and with each other. Bioequivalence of the major tacrolimus metabolite was also assessed. All products fell within the US Food and Drug Administration (FDA) average bioequivalence (ABE) acceptance criteria of a 90% confidence interval contained within the confidence limits of 80.00% and 125.00%. Within-subject variability was similar for the area under the curve (AUC) (range 12.11–15.81) and the concentration maximum (C<sub>max</sub>) (range 17.96–24.72) for all products. The within-subject variability was utilized to calculate the scaled average bioequivalence (SCABE) 90% confidence interval. The calculated SCABE 90% confidence interval was 84.65%–118.13% and 80.00%–125.00% for AUC and C<sub>max</sub>, respectively. The more stringent SCABE acceptance criteria were met for all product comparisons for AUC and C<sub>max</sub> in both individuals with a kidney transplant and those with a liver transplant. European Medicines Agency (EMA) acceptance criteria for narrow therapeutic index drugs were also met, with the only exception being in the case of Brand versus Generic Lo, in which the upper limits of the 90% confidence intervals were 111.30% (kidney) and 112.12% (liver). These were only slightly above the upper EMA acceptance criteria limit for an AUC of 111.11%. SCABE criteria were also met for the major tacrolimus metabolite 13-O-desmethyl tacrolimus for AUC, but it failed the EMA criterion. No acute rejections, no differences in renal function in all individuals, and no differences in liver function were observed in individuals with a liver transplant using the Tukey honest significant difference (HSD) test for multiple comparisons. Fifty-two percent and 65% of all individuals with a kidney or liver transplant, respectively, reported an adverse event. The Exact McNemar test for paired categorical data with adjustments for multiple comparisons was used to compare adverse event rates among the products. No statistically significant differences among any pairs of products were found for any adverse event code or for adverse events overall. Limitations of this study include that the observations were made under strictly controlled conditions that did not allow for the impact of nonadherence or feeding on the possible pharmacokinetic differences. Generic Hi and Lo were selected based upon bioequivalence data in healthy volunteers because no pharmacokinetic data in recipients were available for all products. The safety data should be interpreted in light of the small number of participants and the short observation periods. Lastly, only the 1 mg tacrolimus strength was utilized in this study.</p>
</sec>
<sec id="sec003">
<title>Conclusions</title>
<p>Using an innovative, controlled bioequivalence study design, we observed equivalence between tacrolimus innovator and 2 generic products as well as between 2 generic products in individuals after kidney or liver transplantation following current FDA bioequivalence metrics. These results support the position that bioequivalence for the narrow therapeutic index drug tacrolimus translates from healthy volunteers to individuals receiving a kidney or liver transplant and provides evidence that generic products that are bioequivalent with the innovator product are also bioequivalent to each other.</p>
</sec>
<sec id="sec004">
<title>Trial registration</title>
<p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01889758?term=tacrolimus+generic+alloway&amp;cond=transplant&amp;rank=2" xlink:type="simple">NCT01889758</ext-link>.</p>
</sec>
</abstract>
<abstract abstract-type="toc">
<p>In a randomized 3-treatment crossover clinical trial, Rita Alloway of the University of Cincinnati and colleagues establish bioequivalence between 3 versions of the drug tracolimus (a brand name and 2 disparate generics) in kidney and liver transplant recipients.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<sec id="sec005">
<title>Why was this study done?</title>
<list list-type="bullet">
<list-item><p>Consensus documents developed by professional transplantation societies worldwide have cautioned the use of generic immunosuppressants such as tacrolimus in individuals with a solid organ transplant. Reasons have included repeated switching between innovator (that is, “brand” products) and generics and among different generics, especially when not controlled by physicians.</p></list-item>
<list-item><p>There was uncertainty in the transplant community as to whether tacrolimus generics that are bioequivalent to the innovator are also bioequivalent to each other.</p></list-item>
<list-item><p>For market approval, generic drug products of the narrow therapeutic index drug tacrolimus had to be studied only in healthy individuals and not in the much more complex organ transplant population.</p></list-item>
</list>
</sec>
<sec id="sec006">
<title>What did the researchers do and find?</title>
<list list-type="bullet">
<list-item><p>We performed a randomized, prospective, 3-treatment, 6-period, crossover, replicate dose study in individuals with a kidney or liver transplant.</p></list-item>
<list-item><p>Thirty-five individuals with a kidney transplant and 36 individuals with a liver transplant receiving tacrolimus were studied to compare the tacrolimus time concentration profiles of 3 different products in their blood: namely, Innovator (Prograf), Generic Hi (Sandoz), and Generic Lo (Dr. Reddy) 1.0 mg tacrolimus capsules.</p></list-item>
<list-item><p>Generic products were selected based upon pharmacokinetic data from healthy volunteer studies since bioequivalence data were not available in individuals with an organ transplant.</p></list-item>
<list-item><p>We observed bioequivalence based on average bioequivalence and scaled average bioequivalence criteria in individuals after kidney or liver transplant between tacrolimus innovator and the 2 generics on the US market as well as between the 2 generics.</p></list-item>
</list>
</sec>
<sec id="sec007">
<title>What do these findings mean?</title>
<list list-type="bullet">
<list-item><p>Similar tacrolimus exposure is expected in individuals with a kidney or liver transplant when receiving Prograf, Sandoz generic, or Dr. Reddy’s generic tacrolimus.</p></list-item>
</list>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000038</institution-id>
<institution>U.S. Food and Drug Administration</institution>
</institution-wrap>
</funding-source>
<award-id>U01FD004573</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4835-9197</contrib-id>
<name name-style="western">
<surname>Alloway</surname>
<given-names>Rita Raney</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id>
<institution>National Center for Advancing Translational Sciences</institution>
</institution-wrap>
</funding-source>
<award-id>1UL1TR001425-01</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4835-9197</contrib-id>
<name name-style="western">
<surname>Alloway</surname>
<given-names>Rita Raney</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>On April 27, 2012, the FDA released RFA entitled Pharmacokinetic Studies of Tacrolimus in Patients 9U01 (<ext-link ext-link-type="uri" xlink:href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-12-" xlink:type="simple">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-12-</ext-link> 021.html). Our team was awarded this U01 funded by the United States National Institutes of Health and the Food and Drug Administration: Office of Generic Drugs (U01 FD004573). The funders had no role in study design or data collection and analysis, decision to publish or preparations of the manuscript except that draft guidance documents (Food and Drug Administration. Draft Guidance on Tacrolimus 2014 [cited 2015 December 2]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM406344.pdf" xlink:type="simple">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM406344.pdf</ext-link>.) for analysis of average and scaled average bioequivalence were followed and the Food and Drug Administration independently performed confirmatory analyses of the primary endpoint and dissolution testing and provided comments on the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="5"/>
<page-count count="22"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>Data are available from Rachel Akers at the University of Cincinnati, Data Management Center, for researchers who meet the criteria for access to confidential data. Data are from the Pharmacokinetic Studies of Tacrolimus in Transplant Patients whose authors may be contacted at <email xlink:type="simple">Rachel.akers@cchmc.org</email>.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec008" sec-type="intro">
<title>Introduction</title>
<p>Most individuals receiving a solid organ transplant require lifelong immunosuppression. Switching to generic immunosuppressants may lead to significant savings and improved adherence [<xref ref-type="bibr" rid="pmed.1002428.ref001">1</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref002">2</xref>], which is essential for long-term graft survival [<xref ref-type="bibr" rid="pmed.1002428.ref003">3</xref>]. The current US Food and Drug Administration (FDA) generic drug approval process has performed well [<xref ref-type="bibr" rid="pmed.1002428.ref004">4</xref>]. However, concerns persist regarding whether 2-way crossover studies in healthy individuals using conventional average bioequivalence (ABE) acceptance criteria of a 90% confidence interval contained within the confidence limits of 80.00% to 125.00% are a valid approach for generic immunosuppressant approval for use after transplantation [<xref ref-type="bibr" rid="pmed.1002428.ref005">5</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref006">6</xref>]. This debate started when cyclosporine generics were developed over 15 years ago [<xref ref-type="bibr" rid="pmed.1002428.ref007">7</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref008">8</xref>] and was reinvigorated when tacrolimus generics were approved. Consensus documents developed by professional societies from the US, Europe, and Canada [<xref ref-type="bibr" rid="pmed.1002428.ref009">9</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref012">12</xref>] have cautioned against generic immunosuppressant use, citing (1) the lack of data in transplant recipients, especially “high risk” transplant recipients; (2) the need to implement stricter bioequivalence standards, as tacrolimus is a narrow therapeutic index (NTI) drug for which small changes in dose or exposure can result in therapeutic failure or toxicity; and (3) the lack of bioequivalence data between generics. Molnar et al. published a systematic review and meta-analysis to compare the clinical efficacy and bioequivalence of generic immunosuppressive drugs in individuals with a transplant and concluded that high-quality data were lacking. The authors went further to state that given the serious consequences of rejection and allograft failure, well-designed studies on the bioequivalence and safety of generic immunosuppression in individuals with a transplant are needed [<xref ref-type="bibr" rid="pmed.1002428.ref013">13</xref>].</p>
<p>Differing worldwide bioequivalence regulatory standards for NTI drugs make it difficult to interpret bioequivalence study results [<xref ref-type="bibr" rid="pmed.1002428.ref014">14</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref016">16</xref>]. For NTI drugs, the European Medicines Agency (EMA) requires a narrower 90.00%–111.11% acceptance criterion for the area under the curve (AUC, a measure of actual body exposure to a drug) but uses the usual 80.00%–125.00% acceptance criterion for the concentration maximum (C<sub>max</sub>) for NTI drugs [<xref ref-type="bibr" rid="pmed.1002428.ref014">14</xref>]. Health Canada has adopted standards similar to those of EMA, with an AUC acceptance criterion of 90.00%–112.00% [<xref ref-type="bibr" rid="pmed.1002428.ref015">15</xref>]. The FDA has classified tacrolimus as an NTI drug and recommended the scaled average bioequivalence (SCABE) approach to determine bioequivalence [<xref ref-type="bibr" rid="pmed.1002428.ref016">16</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref017">17</xref>]. With this SCABE approach, both generic and innovator products are given twice with fully replicating measurements in each individual. An innovator pharmaceutical product is the one that was first authorized for marketing on the basis of quality, safety and efficacy. This allows for determination of within-subject variability, which is then used for scaling the bioequivalence acceptance limits based on the reference product for all products tested. This approach creates more stringent bioequivalence criteria: (1) the ABE limits for both AUC and C<sub>max</sub> are narrowed based on the within-subject variability of the reference product and are never wider than 80.00%–125.00%, and (2) the within-subject variabilities of all products are compared to each other.</p>
<p>Tacrolimus has a complex pharmacokinetic profile, as it is metabolized mainly by hepatic and intestinal cytochrome (CYP) P4503A enzymes and over 90% is eliminated as metabolites. CYP3A5 expressers (<italic>CYP3A5 *1/*1 and CYP3A5 *1/*3</italic>) are considered patients who “poorly absorb” and may exhibit higher within-subject variability of tacrolimus pharmacokinetics than nonexpressers (<italic>CYP3A5 *3/*3)</italic>. These genetic differences have been associated with poorer outcomes. Tacrolimus is also a substrate of the drug efflux protein p-glycoprotein, ABCB1, thus impacting tacrolimus exposure [<xref ref-type="bibr" rid="pmed.1002428.ref017">17</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref024">24</xref>]. Because of these complex metabolic and transport processes, stringent ABE testing is used to ensure product excipients do not impact these processes.</p>
<p>Given the aforementioned public concerns [<xref ref-type="bibr" rid="pmed.1002428.ref009">9</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref012">12</xref>], we hypothesized that 2 generic tacrolimus products currently on the US market meet both FDA ABE and SCABE limits in individuals with a kidney or liver transplant when compared to innovator tacrolimus and when compared to each other in a high-quality study. All products met these bioequivalence criteria. In addition, we applied EMA NTI ABE criteria, and all products met the criteria except for one that narrowly fell above the AUC limit.</p>
</sec>
<sec id="sec009" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec010">
<title>Study conduct and oversight</title>
<p>The study design was developed in collaboration with the American Society of Transplantation (Mount Laurel, New Jersey, US), the American Society of Transplant Surgeons (Arlington, Virginia, US), and the FDA. Individuals were recruited from the University of Cincinnati Medical Center and The Christ Hospital in Cincinnati. This trial adhered to the Declaration of Helsinki and was approved by local institutions’ review boards (2012–4891) and the FDA Research Involving Human Subjects Committee (13-018D). All individuals provided written informed consent. The study was monitored locally and by the FDA and registered on clinicaltrials.gov (NCT-01889758). Methodologies for tacrolimus quantification in whole blood (Tables A–F in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref> and Fig A in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>) and genetic polymorphism testing (Table G in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>) are described. The study protocol and statistical analysis plan are also included in the supporting information as <xref ref-type="supplementary-material" rid="pmed.1002428.s002">S1 Text</xref> and <xref ref-type="supplementary-material" rid="pmed.1002428.s003">S2 Text</xref>. Changes from the prespecified analysis plan included the analysis of the minimum concentration (C<sub>min</sub>) in lieu of C<sub>0</sub> and C<sub>12</sub> tacrolimus concentrations as appropriate based upon guidance documents, and dose normalization was not performed because each individual received the same dose in all treatment periods. No interim analyses were conducted prior to these data analyses.</p>
</sec>
<sec id="sec011">
<title>Test product selection</title>
<p>At study initiation, 5 FDA-approved generic tacrolimus products were available in addition to the innovator product, Prograf (Astellas, Northbrook, Illinois) [<xref ref-type="bibr" rid="pmed.1002428.ref025">25</xref>]. Abbreviated New Drug Applications (ANDAs) are submitted to the FDA for all generic products and represent the only data readily available for all products. ANDA data include, but are not limited to, pharmacokinetic data in healthy volunteers that demonstrate bioequivalence between the innovator and generic products by evaluating the pharmacokinetic parameters of AUC and C<sub>max</sub>. Product composition, manufacturing, and pharmacokinetic data for all approved generics were reviewed to identify the 2 most disparate generics. ANDA pharmacokinetic data from each product are provided in Table H-I in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>. Additional manufacturing comparisons are summarized in Table J in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref> [<xref ref-type="bibr" rid="pmed.1002428.ref026">26</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref031">31</xref>]. One tacrolimus product (Panacea; Baddi, India) was FDA-approved but not commercially available, and it was therefore excluded. Pharmacokinetic parameters of AUC and C<sub>max</sub> were examined for the greatest difference between the generic and the innovator product as being the most disparate and named Generic Hi and Generic Lo. Sandoz tacrolimus (Sandoz, Princeton, New Jersey, US) was identified as Generic Hi based upon higher point estimates and higher upper 90% confidence interval compared to innovator. Dr. Reddy tacrolimus (Dr. Reddy, Bachupally, India) was identified as Generic Lo based upon lower point estimates and lowest lower 90% confidence interval compared to innovator. Single tacrolimus 1 mg capsule lots (the most frequently prescribed dosage strength) of Innovator (Prograf), Generic Hi (Sandoz, Princeton, New Jersey, US), and Generic Lo (Dr. Reddy, Bachupally, India) were purchased from a pharmacy wholesaler and controlled by the University of Cincinnati Medical Center Investigational Drug Services. The University of Iowa Pharmaceuticals (Iowa City, Iowa, US), iC42 Clinical Research and Development (Aurora, Colorado, US), and the FDA independently performed dissolution, purity, and content uniformity testing according to applicable US Pharmacopeia Convention guidelines [<xref ref-type="bibr" rid="pmed.1002428.ref029">29</xref>]. Similar results were obtained by both groups. The FDA results are reported in Tables K–O in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>.</p>
</sec>
<sec id="sec012">
<title>Study population, randomization and blinding</title>
<p>Individuals with a kidney or liver transplant included in the present study were at least 18 years old, with stable organ function and no evidence of rejection. Said individuals were at steady state and on stable doses of immunosuppressants including tacrolimus with no expected changes to their immunosuppressive drug regimens to eliminate confounders that occur early post-transplant or during times of rejection. Other eligibility criteria are listed in Section F of <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>. Study participants were stratified by organ type and randomized to 1 of 3 treatment sequences, each including 2 periods of Innovator (Prograf), Generic Hi (Sandoz), and Generic Lo (Dr. Reddy) (<xref ref-type="fig" rid="pmed.1002428.g001">Fig 1</xref>). The replicate dosing design of administering each product twice allowed for analysis of within-subject variability by product. An independent statistician generated a randomization list using SAS (version 9.03, SAS Institute, Cary, North Carolina, US) and provided it to the investigational drug pharmacist. Eligible transplant recipients were recruited from 2 clinical sites, but all screening visits occurred at the University of Cincinnati Medical Center. The investigational drug pharmacist consecutively assigned individuals to a treatment sequence as received, independent of site. All parties were blinded to the randomization sequence allocation until after the pharmacokinetics (PK) analysis was completed. (Additional blinding information is located in Section G of <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>.)</p>
<fig id="pmed.1002428.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Randomization sequence and study design.</title>
<p>PK, pharmacokinetics.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec013">
<title>Treatment protocol</title>
<p>Eligible transplant recipients were screened via telephone. Potential study participants completed a baseline visit, including written informed consent and laboratory, physical, and genetic polymorphism testing (including <italic>CYP3A5*3</italic>, <italic>CYP3A4*1B</italic>, <italic>CYP3A4*22</italic>, <italic>POR*28</italic>, and 3 <italic>ABCB1</italic> SNPs) [<xref ref-type="bibr" rid="pmed.1002428.ref018">18</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref024">24</xref>]. The study assessment schedule is shown in Table P in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>. Study participants were seen 2 weeks later for baseline laboratory examination and randomization and were provided with study drug. Medications were dispensed with a Medication Event Monitoring System (MEMS, AARDEX, Palo Alto, California) bottle cap for electronic monitoring of study medication access. Pill counts were recorded at each pharmacokinetic visit. Individuals were excluded from the analysis if they were nonadherent within 48 hours of PK assessment (Section I in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>).</p>
<p>Tacrolimus doses remained constant during the entire study period. After a 7-day treatment period, individuals underwent a 12-hour tacrolimus pharmacokinetic assessment with dosing and sampling times strictly controlled and monitored. The 7-day treatment period was adequate to reach steady state based upon observed half-life in individuals receiving a kidney or liver transplant. Fifteen tacrolimus samples were collected at C<sub>0</sub> (before the morning dose) and at 20, 40, 60, 80, 100, 120, 140, and 160 minutes and 3, 4, 5, 6, 8, and 12 hours following dosing. Six 12-hour pharmacokinetic assessments were completed after 7 days of administration of each tacrolimus product. All samples were analyzed for tacrolimus and metabolites using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (Sections A and B in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>). All individuals fasted until a standardized meal was allowed after the 4-hour and 12-hour sample collection. At each visit, study participants were assessed for safety lab tests, adverse events, medication adherence, and medication regimen changes (Table P in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>).</p>
</sec>
<sec id="sec014">
<title>Statistical, pharmacokinetic, and bioequivalence analysis</title>
<p>Data were stored electronically using a REDCap database [<xref ref-type="bibr" rid="pmed.1002428.ref032">32</xref>], including all laboratory, patient diary, and bioanalytical data. Data monitoring and analysis plans defined a priori were executed. After data were monitored and all queries resolved, the database was locked. Only individuals completing all 6 pharmacokinetic study periods were analyzed. Actual sample collection times were used for analysis. For each type of organ transplant, a sample size of 24 individuals was required to achieve 90% statistical power for concluding bioequivalence in crossover trials at an alpha of 0.05 using standard bioequivalence limits of 80%–125% and assuming a true difference of 0 [<xref ref-type="bibr" rid="pmed.1002428.ref016">16</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref033">33</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref034">34</xref>].</p>
<p>The primary outcome was to determine whether Innovator (Prograf), Generic Hi (Sandoz), and Generic Lo (Dr. Reddy) tacrolimus products were bioequivalent with each other by comparing their AUC and C<sub>max</sub> using conventional ABE limits (the 90% CIs of the ratio of geometric means of the 2 products for C<sub>max</sub> and AUC were within the range of 80%–125%) [<xref ref-type="bibr" rid="pmed.1002428.ref034">34</xref>] and reference SCABE limits [<xref ref-type="bibr" rid="pmed.1002428.ref016">16</xref>]. The observed C<sub>min</sub> represented the minimum concentration and was analyzed in lieu of C<sub>0</sub> or C<sub>12.</sub> Observed T<sub>max</sub> represented the actual time at which the maximum concentration was measured. Each patient served as his or her own control; therefore, dose normalization was not required. The investigators and the FDA independently analyzed the primary end-point data using WinNonlin software (version 6.4. Phoenix, Certara, Princeton, New Jersey, US) and SAS (version 9.3, SAS Institute, Cary, North Carolina), respectively. The investigators’ analysis results are reported.</p>
<p>Secondary outcomes included ABE and SCABE assessment in prespecified subgroups and assessments for safety and efficacy. Subgroups in which there were at least 6 recipients and the statistical model converged are reported. The prespecified subgroups included recipient sex; age; African-American race; diabetes; CYP3A4/5, POR 28, and ABCB1 polymorphisms; and donor CYP3A5, as these subgroups are reported to strongly influence tacrolimus concentrations [<xref ref-type="bibr" rid="pmed.1002428.ref018">18</xref>]. The study was not powered to identify differences by subgroup. In addition, pharmacokinetic parameters of the primary tacrolimus metabolite, 13-O-desmethyl tacrolimus, were compared.</p>
<p>Safety was assessed at baseline and weekly throughout the study by complete metabolic panels and complete blood cell count with differential. Baseline and weekly assessments included markers of transplant function in individuals with a kidney transplant (creatinine) or liver transplant (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and alkaline phosphatase). To compare kidney and liver function tests among products, a mixed effects model was run with a term designating the product received in each period and a random subject term and using the Tukey’s honest significant difference (HSD) test for multiple comparisons, where needed [<xref ref-type="bibr" rid="pmed.1002428.ref035">35</xref>]. The study was not powered to assess differences in transplant organ function. Total daily tacrolimus dose data were summarized using means and standard deviation, and between-group differences were analyzed using the <italic>t</italic> test. Reports of adverse events were collected at each visit and coded utilizing the Common Terminology Criteria for Adverse Events (CTCAE v4.0) [<xref ref-type="bibr" rid="pmed.1002428.ref036">36</xref>]. The Exact McNemar test for paired categorical data with adjustments for multiple comparisons was used to compare adverse event rates among the products [<xref ref-type="bibr" rid="pmed.1002428.ref037">37</xref>]. No statistically significant differences among any pairs of products were found for any adverse event code or for adverse events overall.</p>
<p>ABE was assessed within each transplant organ group (i.e., kidney and liver) by using a mixed effects analysis of variance model for a 6-period crossover design with the log<sub>e</sub>-transformed pharmacokinetic parameter estimates (AUC, C<sub>max</sub>, and C<sub>min</sub>) as the response variable. Fixed effect terms in the model included sequence, period, and treatment. Random effects included subject nested within sequence. The error variance structure accounted for the repeated measures of treatments within each subject. Two-sided 90% confidence intervals using the differences in least square means and the appropriate error terms from the model were calculated for each pairwise assessment of bioequivalence. The estimates and end points of the confidence intervals were back-transformed to obtain the ratios of the parameters being assessed for bioequivalence and the corresponding 90% confidence interval for the ratios. If the entire confidence interval was contained within the range of 80% to 125%, then ABE was established.</p>
<p>To assess SCABE, the estimate of within-subject variability for each treatment was obtained by using a mixed effects model within each organ type and treatment group. Fixed effect terms included sequence, replication (i.e., first or second), and sequence-by-replication interaction. Random effect terms include subject nested within sequence. This model provided estimates of the within-subject variability for each treatment, and these were then used to adjust the bioequivalence end points to obtain the SCABE limits and calculate the criterion bound in accordance with FDA guidance for NTI drugs [<xref ref-type="bibr" rid="pmed.1002428.ref016">16</xref>]. SCABE was concluded if each of the following criteria were met: (1) the 2-sided 90% confidence interval calculated for the ABE assessment must fall entirely within the SCABE limits, (2) the criterion bound must be less than 0, and (3) the upper 90% confidence limit for the ratio of the within-subject variabilities for the 2 treatments being assessed must be less than 2.5 [<xref ref-type="bibr" rid="pmed.1002428.ref016">16</xref>].</p>
</sec>
</sec>
<sec id="sec015" sec-type="results">
<title>Results</title>
<sec id="sec016">
<title>Study individuals</title>
<p>From December 2013 through October 2014, 42 individuals with a kidney transplant and 40 individuals with a liver transplant were consented and followed as per the study protocol. Seventy-one individuals were analyzable (kidney, <italic>n</italic> = 35; liver, <italic>n</italic> = 36). The most frequent causes of noneligibility during screening were (1) a greater than 3-hour drive from the study center, (2) receiving the 0.5-mg tacrolimus dosage form, (3) renal function &lt; 35 ml/min, (4) not receiving tacrolimus, (5) a history of multiorgan transplant (i.e., kidney and pancreas or liver and kidney), (6) documented nonadherence, or (7) a history of cancer. Moreover, individuals with a liver transplant and active hepatitis C were not eligible. A complete list of inclusion and exclusion criteria is in Section F in <xref ref-type="supplementary-material" rid="pmed.1002428.s004">S1 Appendix</xref>. Consolidated Standards Of Reporting Trials (CONSORT) flow diagrams (<xref ref-type="fig" rid="pmed.1002428.g002">Fig 2</xref>) and checklist (<xref ref-type="supplementary-material" rid="pmed.1002428.s001">S1 CONSORT Checklist</xref>) are provided.</p>
<fig id="pmed.1002428.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.g002</object-id>
<label>Fig 2</label>
<caption>
<title/>
<p><bold>Kidney (A) and liver (B) Consolidated Standards Of Reporting Trials (CONSORT) flow diagram.</bold> (A) Individuals with a kidney transplant. (B) Individuals with a liver transplant. LFT, liver function tests; PI, principal investigator; PK, pharmacokinetics; SCr, serum creatinine; UTI, urinary tract infection.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.g002" xlink:type="simple"/>
</fig>
<p>The demographic and baseline characteristics reported to impact the tacrolimus pharmacokinetics of the analyzed individuals are summarized in <xref ref-type="table" rid="pmed.1002428.t001">Table 1</xref> and were similar to intent-to-treat individuals (Table Q in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>). Most individuals received tacrolimus, mycophenolate, and corticosteroid-free immunosuppression. Immunosuppressive regimens, including tacrolimus doses, remained constant throughout the 6-week study. Individuals with a kidney or liver transplant received a median mg/day (IQR) tacrolimus dose of 5.0 (4.0–8.0) or 4.0 (3.0–6.0), respectively. During the study, no patient initiated, discontinued, or changed doses of known CYP3A inhibitors or inducers that could impact pharmacokinetic observations.</p>
<table-wrap id="pmed.1002428.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.t001</object-id>
<label>Table 1</label> <caption><title>Demographic and baseline characteristics of analyzed study individuals with a kidney or liver transplant.</title></caption>
<alternatives>
<graphic id="pmed.1002428.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="center">Individuals with a kidney transplant (<italic>n</italic> = 35)</th>
<th align="center">Individuals with a liver transplant (<italic>n</italic> = 36)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Age (y) median (IQR)</bold></td>
<td align="center">52 (39.0–59.0)</td>
<td align="center">57 (48.5–61.0)</td>
</tr>
<tr>
<td align="left"><bold>Gender (male)</bold></td>
<td align="center">65.7%</td>
<td align="center">47.2%</td>
</tr>
<tr>
<td align="left"><bold>Race (African American)</bold></td>
<td align="center">17.1%</td>
<td align="center">2.8%</td>
</tr>
<tr>
<td align="left"><bold>Transplant donor type</bold></td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="right"><bold>Deceased</bold></td>
<td align="center">25.7%</td>
<td align="center">100%</td>
</tr>
<tr>
<td align="right"><bold>Living related</bold></td>
<td align="center">34.3%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="right"><bold>Living unrelated</bold></td>
<td align="center">40%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><bold>Time post-transplant (y) median (IQR)</bold></td>
<td align="center">4.5 (3.3–7.9)</td>
<td align="center">3.2 (1.8–6.9)</td>
</tr>
<tr>
<td align="left"><bold>Presence of diabetes (%)</bold></td>
<td align="center">37.1</td>
<td align="center">27.8</td>
</tr>
<tr>
<td align="left"><bold>Maintenance immunosuppression</bold></td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="right"><bold>Steroids (%)</bold></td>
<td align="center">14.3</td>
<td align="center">8.3</td>
</tr>
<tr>
<td align="right"><bold>Mycophenolic acid (%)</bold></td>
<td align="center">100</td>
<td align="center">88.9</td>
</tr>
<tr>
<td align="right"><bold>Median mg/d tacrolimus dose (IQR)</bold></td>
<td align="center">5.0 (4.0–8.0)</td>
<td align="center">4.0 (3.0–6.0)</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec017">
<title>Adherence monitoring</title>
<p>Adherence was evaluated using the MEMS system to insure the quality of the pharmacokinetic evaluations. Adherence was defined as the degree to which the number of medication doses taken each day matched the number of prescribed doses. Over 6 weeks, MEMS-based adherence was 99.75% (range: 97.67%–100%). Three individuals were excluded from the analysis due to nonadherence (kidney, <italic>n</italic> = 1; liver, <italic>n</italic> = 2) (<xref ref-type="fig" rid="pmed.1002428.g002">Fig 2</xref>). MEMS-based adherence rates are reported in Tables R and S in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>.</p>
</sec>
<sec id="sec018">
<title>ABE, SCABE, and within-subject variability comparison</title>
<p>Tacrolimus 12-hour concentrations following chronic dosing are presented for individuals with a kidney (<xref ref-type="fig" rid="pmed.1002428.g003">Fig 3A</xref>) or liver transplant (<xref ref-type="fig" rid="pmed.1002428.g003">Fig 3B</xref>). Two tacrolimus concentration-time curves for each product are depicted, representing the first and second exposures to the product. Values for the mean and the standard deviation (SD) for each pharmacokinetic time point are reported in <xref ref-type="table" rid="pmed.1002428.t002">Table 2</xref>. There were no statistically significant differences observed by product between time points as assessed by Kruskal-Wallis [<xref ref-type="bibr" rid="pmed.1002428.ref038">38</xref>].</p>
<fig id="pmed.1002428.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Comparison of tacrolimus time concentration curves by product.</title>
<p>(A) Individuals with a kidney transplant. (B) Individuals with a liver transplant. Fifteen tacrolimus blood samples were collected at C<sub>0</sub> (before the morning dose) and at 20, 40, 60 (1 hour), 80, 100, 120 (2 hours), 140, 160, and 180 (3 hours) minutes and 4, 5, 6, 8, and 12 hours to construct the tacrolimus concentration-time curves. Each tacrolimus product—Innovator, Generic Hi, and Generic Lo—was administered according to the randomly assigned treatment sequence (<xref ref-type="fig" rid="pmed.1002428.g001">Fig 1</xref>) twice for 1 week before collection of steady-state pharmacokinetic profiles. Each point on the curve displays the tacrolimus mean whole blood concentrations; standard deviations are depicted by error bars. There were no statistically significant differences between any time points.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.g003" xlink:type="simple"/>
</fig>
<table-wrap id="pmed.1002428.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.t002</object-id>
<label>Table 2</label> <caption><title>Tacrolimus level results at each time point for individuals with a kidney or liver transplant.</title></caption>
<alternatives>
<graphic id="pmed.1002428.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="14" style="background-color:#E7E6E6">Individuals with a kidney transplant</th>
</tr>
<tr>
<th align="left" rowspan="3"><break/>PK time point (min/h)</th>
<th align="center" colspan="4">Innovator</th>
<th align="center" colspan="4">Generic Hi</th>
<th align="center" colspan="4">Generic Lo</th>
<th align="center" rowspan="3"><break/><italic>p</italic>-Value</th>
</tr>
<tr>
<th align="center" colspan="2">First exposure</th>
<th align="center" colspan="2">Second exposure</th>
<th align="center" colspan="2">First exposure</th>
<th align="center" colspan="2">Second exposure</th>
<th align="center" colspan="2">First exposure</th>
<th align="center" colspan="2">Second exposure</th>
</tr>
<tr>
<th align="left">Mean ng/ml</th>
<th align="left">SD</th>
<th align="left">Mean ng/ml</th>
<th align="left">SD</th>
<th align="left">Mean ng/ml</th>
<th align="left">SD</th>
<th align="left">Mean ng/ml</th>
<th align="left">SD</th>
<th align="left">Mean ng/ml</th>
<th align="left">SD</th>
<th align="left">Mean ng/ml</th>
<th align="left">SD</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">0</td>
<td align="left">6.1</td>
<td align="left">2.2</td>
<td align="left">5.3</td>
<td align="left">1.5</td>
<td align="left">6.1</td>
<td align="left">2.0</td>
<td align="left">5.7</td>
<td align="left">1.7</td>
<td align="left">6.2</td>
<td align="left">1.8</td>
<td align="left">5.6</td>
<td align="left">1.7</td>
<td align="left">0.36</td>
</tr>
<tr>
<td align="left">20 min</td>
<td align="left">6.5</td>
<td align="left">2.5</td>
<td align="left">5.8</td>
<td align="left">2.0</td>
<td align="left">6.8</td>
<td align="left">2.3</td>
<td align="left">6.9</td>
<td align="left">4.0</td>
<td align="left">7.4</td>
<td align="left">3.3</td>
<td align="left">6.8</td>
<td align="left">3.0</td>
<td align="left">0.25</td>
</tr>
<tr>
<td align="left">40 min</td>
<td align="left">9.7</td>
<td align="left">4.9</td>
<td align="left">9.0</td>
<td align="left">4.9</td>
<td align="left">11.2</td>
<td align="left">6.0</td>
<td align="left">11.6</td>
<td align="left">8.8</td>
<td align="left">12.9</td>
<td align="left">6.8</td>
<td align="left">11.5</td>
<td align="left">6.4</td>
<td align="left">0.06</td>
</tr>
<tr>
<td align="left">1 h</td>
<td align="left">12.2</td>
<td align="left">7.4</td>
<td align="left">12.3</td>
<td align="left">8.4</td>
<td align="left">14.7</td>
<td align="left">9.2</td>
<td align="left">13.7</td>
<td align="left">7.6</td>
<td align="left">16.0</td>
<td align="left">8.0</td>
<td align="left">13.9</td>
<td align="left">6.7</td>
<td align="left">0.11</td>
</tr>
<tr>
<td align="left">80 min</td>
<td align="left">13.2</td>
<td align="left">7.1</td>
<td align="left">13.3</td>
<td align="left">7.4</td>
<td align="left">15.6</td>
<td align="left">9.6</td>
<td align="left">14.4</td>
<td align="left">6.9</td>
<td align="left">16.6</td>
<td align="left">8.2</td>
<td align="left">14.1</td>
<td align="left">5.4</td>
<td align="left">0.33</td>
</tr>
<tr>
<td align="left">100 min</td>
<td align="left">14.0</td>
<td align="left">8.2</td>
<td align="left">13.3</td>
<td align="left">5.9</td>
<td align="left">15.6</td>
<td align="left">8.7</td>
<td align="left">13.9</td>
<td align="left">5.8</td>
<td align="left">16.0</td>
<td align="left">8.1</td>
<td align="left">13.4</td>
<td align="left">4.5</td>
<td align="left">0.72</td>
</tr>
<tr>
<td align="left">2 h</td>
<td align="left">13.6</td>
<td align="left">7.4</td>
<td align="left">13.2</td>
<td align="left">5.6</td>
<td align="left">14.6</td>
<td align="left">7.0</td>
<td align="left">13.1</td>
<td align="left">5.0</td>
<td align="left">15.2</td>
<td align="left">7.9</td>
<td align="left">13.0</td>
<td align="left">4.1</td>
<td align="left">0.86</td>
</tr>
<tr>
<td align="left">140 min</td>
<td align="left">13.1</td>
<td align="left">6.7</td>
<td align="left">12.7</td>
<td align="left">5.0</td>
<td align="left">14.5</td>
<td align="left">6.5</td>
<td align="left">12.1</td>
<td align="left">4.5</td>
<td align="left">14.3</td>
<td align="left">7.3</td>
<td align="left">12.0</td>
<td align="left">3.6</td>
<td align="left">0.76</td>
</tr>
<tr>
<td align="left">160 min</td>
<td align="left">12.9</td>
<td align="left">6.8</td>
<td align="left">11.7</td>
<td align="left">4.6</td>
<td align="left">13.6</td>
<td align="left">5.9</td>
<td align="left">11.4</td>
<td align="left">3.8</td>
<td align="left">13.7</td>
<td align="left">7.4</td>
<td align="left">11.6</td>
<td align="left">3.5</td>
<td align="left">0.72</td>
</tr>
<tr>
<td align="left">3 h</td>
<td align="left">12.3</td>
<td align="left">5.9</td>
<td align="left">11.0</td>
<td align="left">3.7</td>
<td align="left">12.6</td>
<td align="left">5.2</td>
<td align="left">11.0</td>
<td align="left">3.9</td>
<td align="left">13.1</td>
<td align="left">7.0</td>
<td align="left">11.0</td>
<td align="left">3.6</td>
<td align="left">0.79</td>
</tr>
<tr>
<td align="left">4 h</td>
<td align="left">9.9</td>
<td align="left">3.8</td>
<td align="left">9.0</td>
<td align="left">3.0</td>
<td align="left">10.4</td>
<td align="left">3.3</td>
<td align="left">9.3</td>
<td align="left">3.1</td>
<td align="left">10.7</td>
<td align="left">4.8</td>
<td align="left">9.3</td>
<td align="left">3.5</td>
<td align="left">0.37</td>
</tr>
<tr>
<td align="left">5 h</td>
<td align="left">8.2</td>
<td align="left">3.0</td>
<td align="left">7.7</td>
<td align="left">2.3</td>
<td align="left">8.8</td>
<td align="left">2.7</td>
<td align="left">8.0</td>
<td align="left">2.4</td>
<td align="left">8.9</td>
<td align="left">3.2</td>
<td align="left">7.8</td>
<td align="left">2.3</td>
<td align="left">0.44</td>
</tr>
<tr>
<td align="left">6 h</td>
<td align="left">7.4</td>
<td align="left">2.4</td>
<td align="left">7.1</td>
<td align="left">2.3</td>
<td align="left">7.9</td>
<td align="left">2.5</td>
<td align="left">7.2</td>
<td align="left">2.1</td>
<td align="left">7.9</td>
<td align="left">2.8</td>
<td align="left">7.0</td>
<td align="left">2.0</td>
<td align="left">0.54</td>
</tr>
<tr>
<td align="left">8 h</td>
<td align="left">6.6</td>
<td align="left">2.2</td>
<td align="left">6.2</td>
<td align="left">1.9</td>
<td align="left">6.9</td>
<td align="left">2.2</td>
<td align="left">6.2</td>
<td align="left">1.6</td>
<td align="left">6.9</td>
<td align="left">2.3</td>
<td align="left">6.2</td>
<td align="left">1.7</td>
<td align="left">0.50</td>
</tr>
<tr>
<td align="left">12 h</td>
<td align="left">5.6</td>
<td align="left">1.8</td>
<td align="left">5.2</td>
<td align="left">1.6</td>
<td align="left">5.9</td>
<td align="left">1.8</td>
<td align="left">5.3</td>
<td align="left">1.3</td>
<td align="left">5.9</td>
<td align="left">2.1</td>
<td align="left">5.3</td>
<td align="left">1.3</td>
<td align="left">0.51</td>
</tr>
<tr>
<td align="left" colspan="14" style="background-color:#E7E6E6"><bold>Individuals with a liver transplant</bold></td>
</tr>
<tr>
<td align="left">0</td>
<td align="left">4.1</td>
<td align="left">1.6</td>
<td align="left">3.9</td>
<td align="left">1.5</td>
<td align="left">4.3</td>
<td align="left">1.7</td>
<td align="left">4.5</td>
<td align="left">2.5</td>
<td align="left">4.2</td>
<td align="left">1.7</td>
<td align="left">4.2</td>
<td align="left">1.7</td>
<td align="left">0.90</td>
</tr>
<tr>
<td align="left">20 min</td>
<td align="left">4.5</td>
<td align="left">1.9</td>
<td align="left">4.7</td>
<td align="left">1.8</td>
<td align="left">5.0</td>
<td align="left">2.0</td>
<td align="left">5.3</td>
<td align="left">2.6</td>
<td align="left">5.0</td>
<td align="left">2.2</td>
<td align="left">5.4</td>
<td align="left">2.5</td>
<td align="left">0.57</td>
</tr>
<tr>
<td align="left">40 min</td>
<td align="left">7.7</td>
<td align="left">4.4</td>
<td align="left">7.8</td>
<td align="left">4.5</td>
<td align="left">9.7</td>
<td align="left">4.9</td>
<td align="left">9.5</td>
<td align="left">5.6</td>
<td align="left">9.1</td>
<td align="left">4.9</td>
<td align="left">10.9</td>
<td align="left">6.6</td>
<td align="left">0.18</td>
</tr>
<tr>
<td align="left">1 h</td>
<td align="left">10.5</td>
<td align="left">6.7</td>
<td align="left">9.5</td>
<td align="left">5.3</td>
<td align="left">11.7</td>
<td align="left">6.2</td>
<td align="left">11.5</td>
<td align="left">7.4</td>
<td align="left">11.8</td>
<td align="left">6.9</td>
<td align="left">12.3</td>
<td align="left">7.5</td>
<td align="left">0.53</td>
</tr>
<tr>
<td align="left">80 min</td>
<td align="left">11.4</td>
<td align="left">6.6</td>
<td align="left">9.9</td>
<td align="left">5.4</td>
<td align="left">11.4</td>
<td align="left">6.1</td>
<td align="left">11.4</td>
<td align="left">7.3</td>
<td align="left">12.4</td>
<td align="left">7.8</td>
<td align="left">11.3</td>
<td align="left">6.0</td>
<td align="left">0.85</td>
</tr>
<tr>
<td align="left">100 min</td>
<td align="left">11.1</td>
<td align="left">6.0</td>
<td align="left">9.5</td>
<td align="left">5.0</td>
<td align="left">10.9</td>
<td align="left">6.0</td>
<td align="left">10.6</td>
<td align="left">6.2</td>
<td align="left">11.4</td>
<td align="left">7.2</td>
<td align="left">10.4</td>
<td align="left">5.1</td>
<td align="left">0.91</td>
</tr>
<tr>
<td align="left">2 h</td>
<td align="left">10.5</td>
<td align="left">5.2</td>
<td align="left">8.9</td>
<td align="left">4.5</td>
<td align="left">10.2</td>
<td align="left">5.9</td>
<td align="left">9.4</td>
<td align="left">5.2</td>
<td align="left">10.7</td>
<td align="left">6.7</td>
<td align="left">9.5</td>
<td align="left">4.3</td>
<td align="left">0.80</td>
</tr>
<tr>
<td align="left">140 min</td>
<td align="left">9.7</td>
<td align="left">4.6</td>
<td align="left">8.2</td>
<td align="left">4.1</td>
<td align="left">9.3</td>
<td align="left">5.3</td>
<td align="left">8.4</td>
<td align="left">4.4</td>
<td align="left">9.7</td>
<td align="left">5.9</td>
<td align="left">8.7</td>
<td align="left">3.7</td>
<td align="left">0.68</td>
</tr>
<tr>
<td align="left">160 min</td>
<td align="left">8.8</td>
<td align="left">4.0</td>
<td align="left">7.6</td>
<td align="left">3.8</td>
<td align="left">8.5</td>
<td align="left">4.7</td>
<td align="left">7.8</td>
<td align="left">3.9</td>
<td align="left">9.1</td>
<td align="left">5.4</td>
<td align="left">8.0</td>
<td align="left">3.4</td>
<td align="left">0.72</td>
</tr>
<tr>
<td align="left">3 h</td>
<td align="left">8.1</td>
<td align="left">3.6</td>
<td align="left">7.3</td>
<td align="left">3.6</td>
<td align="left">8.0</td>
<td align="left">4.4</td>
<td align="left">7.4</td>
<td align="left">3.5</td>
<td align="left">8.5</td>
<td align="left">4.9</td>
<td align="left">7.5</td>
<td align="left">3.1</td>
<td align="left">0.81</td>
</tr>
<tr>
<td align="left">4 h</td>
<td align="left">6.4</td>
<td align="left">2.7</td>
<td align="left">6.1</td>
<td align="left">3.1</td>
<td align="left">6.5</td>
<td align="left">3.3</td>
<td align="left">6.4</td>
<td align="left">2.8</td>
<td align="left">6.9</td>
<td align="left">3.7</td>
<td align="left">6.2</td>
<td align="left">2.4</td>
<td align="left">0.89</td>
</tr>
<tr>
<td align="left">5 h</td>
<td align="left">5.5</td>
<td align="left">2.2</td>
<td align="left">5.3</td>
<td align="left">2.5</td>
<td align="left">5.6</td>
<td align="left">2.7</td>
<td align="left">5.5</td>
<td align="left">2.5</td>
<td align="left">5.9</td>
<td align="left">2.8</td>
<td align="left">5.4</td>
<td align="left">2.0</td>
<td align="left">0.95</td>
</tr>
<tr>
<td align="left">6 h</td>
<td align="left">4.9</td>
<td align="left">1.9</td>
<td align="left">4.7</td>
<td align="left">2.1</td>
<td align="left">5.1</td>
<td align="left">2.3</td>
<td align="left">5.1</td>
<td align="left">2.4</td>
<td align="left">5.4</td>
<td align="left">2.4</td>
<td align="left">4.9</td>
<td align="left">1.9</td>
<td align="left">0.88</td>
</tr>
<tr>
<td align="left">8 h</td>
<td align="left">4.3</td>
<td align="left">1.7</td>
<td align="left">4.2</td>
<td align="left">1.8</td>
<td align="left">4.6</td>
<td align="left">2.1</td>
<td align="left">4.5</td>
<td align="left">2.0</td>
<td align="left">4.7</td>
<td align="left">2.1</td>
<td align="left">4.4</td>
<td align="left">1.7</td>
<td align="left">0.92</td>
</tr>
<tr>
<td align="left">12 h</td>
<td align="left">3.7</td>
<td align="left">1.5</td>
<td align="left">3.6</td>
<td align="left">1.5</td>
<td align="left">3.9</td>
<td align="left">1.7</td>
<td align="left">3.9</td>
<td align="left">1.8</td>
<td align="left">3.9</td>
<td align="left">1.8</td>
<td align="left">3.7</td>
<td align="left">1.4</td>
<td align="left">0.96</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>PK, pharmacokinetics; SD, standard deviation.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Pharmacokinetic parameters for individuals with a kidney or liver transplant by product are summarized in <xref ref-type="table" rid="pmed.1002428.t003">Table 3</xref>. Point estimates of the geometric means with the resulting 2-sided 95% confidence intervals are presented for AUC, C<sub>max</sub>, C<sub>min</sub>, and T<sub>max</sub> by product. Product selection was based upon pharmacokinetic studies in healthy individuals as previously described. The Generic Hi (Sandoz) observed exposure was numerically higher than that of Innovator in both individuals with a kidney transplant and those with a liver transplant. In this study, the point estimate for Generic Lo exposure was numerically higher than that of both Innovator and Generic Hi in both individuals with a kidney transplant and those with a liver transplant. However, this can be expected to be caused by random variability since these products were shown to be bioequivalent. (<xref ref-type="table" rid="pmed.1002428.t003">Table 3</xref>)</p>
<table-wrap id="pmed.1002428.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.t003</object-id>
<label>Table 3</label> <caption><title>Comparison of key pharmacokinetic parameters after administration of the different tacrolimus products.</title></caption>
<alternatives>
<graphic id="pmed.1002428.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="center" colspan="5" style="background-color:#D9D9D9"><bold>Individuals with a kidney transplant</bold></td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>PK metrics</bold></td>
<td align="center" colspan="4"><bold>Point estimate geometric mean (95% confidence interval)</bold></td>
</tr>
<tr>
<td align="center"><bold>Innovator</bold></td>
<td align="center" colspan="2"><bold>Generic Hi</bold></td>
<td align="center"><bold>Generic Lo</bold></td>
</tr>
<tr>
<td align="center"><bold>AUC</bold><xref ref-type="table-fn" rid="t003fn002"><sup><bold>1</bold></sup></xref> <bold>(ng*h/ml)</bold></td>
<td align="center">92.86 (83.41–103.38)</td>
<td align="center" colspan="2">97.93 (88.33–108.58)</td>
<td align="center">98.38 (88.57–109.28)</td>
</tr>
<tr>
<td align="center"><bold>C</bold><sub><bold>MAX</bold></sub><xref ref-type="table-fn" rid="t003fn003"><sup><bold>2</bold></sup></xref> <bold>(ng/ml)</bold></td>
<td align="center">14.47 (12.57–16.65)</td>
<td align="center" colspan="2">15.72 (13.67–18.08)</td>
<td align="center">15.88 (13.79–18.30)</td>
</tr>
<tr>
<td align="center"><bold>C</bold><sub><bold>MIN</bold></sub><xref ref-type="table-fn" rid="t003fn003"><sup><bold>2</bold></sup></xref> <bold>(ng/ml)</bold></td>
<td align="center">4.89 (4.42–5.41)</td>
<td align="center" colspan="2">5.13 (4.67–5.63)</td>
<td align="center">5.11 (4.65–5.61)</td>
</tr>
<tr>
<td align="center"><bold>T</bold><sub><bold>MAX</bold></sub><sup><bold>3</bold></sup> <bold>(h)</bold></td>
<td align="center">1.70 (1.50–1.94)</td>
<td align="center" colspan="2">1.47 (1.27–1.70)</td>
<td align="center">1.48 (1.28–1.72)</td>
</tr>
<tr>
<td align="center" colspan="5" style="background-color:#D9D9D9"><bold>Individuals with a liver transplant</bold></td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>PK metrics</bold></td>
<td align="center" colspan="4"><bold>Point estimate geometric mean (95% confidence interval)</bold></td>
</tr>
<tr>
<td align="center"><bold>Innovator</bold></td>
<td align="center" colspan="2"><bold>Generic Hi</bold></td>
<td align="center"><bold>Generic Lo</bold></td>
</tr>
<tr>
<td align="center"><bold>AUC</bold><xref ref-type="table-fn" rid="t003fn002"><sup><bold>1</bold></sup></xref> <bold>(ng*h/ml)</bold></td>
<td align="center">62.26 (53.87–71.96)</td>
<td align="center" colspan="2">65.26 (56.02–76.01)</td>
<td align="center">66.87 (57.70–77.49)</td>
</tr>
<tr>
<td align="center"><bold>C</bold><sub><bold>MAX</bold></sub><xref ref-type="table-fn" rid="t003fn003"><sup><bold>2</bold></sup></xref> <bold>(ng/ml)</bold></td>
<td align="center">10.49 (8.92–12.34)</td>
<td align="center" colspan="2">11.16 (9.38–13.29)</td>
<td align="center">11.73 (9.85–13.97)</td>
</tr>
<tr>
<td align="center"><bold>C</bold><sub><bold>MIN</bold></sub><xref ref-type="table-fn" rid="t003fn003"><sup><bold>2</bold></sup></xref> <bold>(ng/ml)</bold></td>
<td align="center">3.26 (2.83–3.76)</td>
<td align="center" colspan="2">3.49 (3.00–4.05)</td>
<td align="center">3.42 (2.96–3.94)</td>
</tr>
<tr>
<td align="center"><bold>T</bold><sub><bold>MAX</bold></sub><xref ref-type="table-fn" rid="t003fn004"><sup><bold>3</bold></sup></xref> <bold>(h)</bold></td>
<td align="center">1.35 (1.19–1.52)</td>
<td align="center" colspan="2">1.16 (1.00–1.34)</td>
<td align="center">1.19 (1.05–1.35)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>AUC, area under the curve; PK, pharmacokinetics.</p></fn>
<fn id="t003fn002"><p><sup>1</sup>AUC is quantified by the units of tacrolimus concentration (ng/ml) over time (h).</p></fn>
<fn id="t003fn003"><p><sup>2</sup>The C<sub>MAX</sub> and the C<sub>MIN</sub> tacrolimus concentrations are reported in units of ng/ml and represent the highest and lowest observed concentration, respectively.</p></fn>
<fn id="t003fn004"><p><sup>3</sup>T<sub>max </sub>is the time the maximum concentration is observed and is reported in hours (h).</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The primary end point of bioequivalence of these pharmacokinetic parameters was tested using SCABE on log-transformed data. When comparing Innovator with Generic Hi and Generic Lo, and Generic Hi with Generic Lo, AUC, C<sub>max</sub>, and C<sub>min</sub> fell within conventional ABE limits of 80%–125%, as well as within the tighter SCABE acceptance limits. Comparing interindividual variability of systemic tacrolimus exposure (AUC), within-subject variability ranged from 12.11% to 15.81%. Similarly, C<sub>max</sub> within-subject variability ranged from 17.96% to 24.72% for all products. Per the FDA guidance for SCABE testing, all products exhibited similar pharmacokinetic variability since the upper limit of the 90% confidence interval for the ratio of within-subject variability was equal to or less than 2.5 (Tables <xref ref-type="table" rid="pmed.1002428.t004">4</xref> and <xref ref-type="table" rid="pmed.1002428.t005">5</xref>). SCABE criteria were met for all product comparisons for AUC and C<sub>max</sub> in both individuals with a kidney and those with a liver transplant. In reference to the EMA bioequivalence acceptance range for AUC of 90.00%–111.11%, these limits were met, with the only exception being in the case of Innovator versus Generic Lo. Here the upper limits of the 90% -confidence intervals—111.30% (kidney) and 112.12% (liver)—were slightly above the upper EMA AUC acceptance criterion [<xref ref-type="bibr" rid="pmed.1002428.ref014">14</xref>], whereas only Innovator versus Generic Lo in liver transplant recipients was also above the Health Canada AUC bioequivalence acceptance limits for critical dose drugs of 90%–112%[<xref ref-type="bibr" rid="pmed.1002428.ref015">15</xref>].</p>
<table-wrap id="pmed.1002428.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.t004</object-id>
<label>Table 4</label> <caption><title>Results of bioequivalence testing using average bioequivalence (ABE) and scaled average bioequivalence (SCABE) metrics for the area under the curve (AUC) (A), maximum concentration (C<sub>max</sub>) (B), and the minimum concentration (C<sub>min</sub>) (C) in individuals with a kidney transplant.</title></caption>
<alternatives>
<graphic id="pmed.1002428.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="center" colspan="10" style="background-color:#D9D9D9"><bold>(A) AUC</bold></td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Reference</bold></td>
<td align="center" rowspan="2"><bold>Test</bold></td>
<td align="center" rowspan="2"><bold>AUC geometric mean ratio (%)</bold></td>
<td align="center" rowspan="2"><bold>Reference within-subject variability (S</bold><sub><bold>WR,</bold></sub> <bold>%)</bold></td>
<td align="center" rowspan="2"><bold>Observed 90% confidence interval</bold></td>
<td align="center" rowspan="2"><bold>Confidence bound</bold></td>
<td align="center" rowspan="2"><bold>SCABE limit</bold></td>
<td align="center" rowspan="2"><bold>Variability comparison (<xref ref-type="table-fn" rid="t004fn002"><sup>1</sup></xref>statistics of σ<sub>WT</sub>/σ<sub>WR</sub>)</bold></td>
<td align="center" colspan="2"><bold>Product approval standards</bold></td>
</tr>
<tr>
<td align="center"><bold>FDA</bold><xref ref-type="table-fn" rid="t004fn003"><sup><bold>2</bold></sup></xref></td>
<td align="center"><bold>EMA</bold><xref ref-type="table-fn" rid="t004fn004"><sup><bold>3</bold></sup></xref></td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">105.47</td>
<td align="center">12.11</td>
<td align="center">101.44–109.65</td>
<td align="center">−0.0060</td>
<td align="center">88.02–113.61</td>
<td align="center">1.62</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">105.95</td>
<td align="center">12.11</td>
<td align="center">100.85–111.30</td>
<td align="center">−0.0035</td>
<td align="center">88.02–113.61</td>
<td align="center">1.75</td>
<td align="center">Pass</td>
<td align="center">Fail</td>
</tr>
<tr>
<td align="center">Generic<break/>Hi</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">100.46</td>
<td align="center">14.62</td>
<td align="center">95.45–105.72</td>
<td align="center">−0.0163</td>
<td align="center">85.72–116.65</td>
<td align="center">1.45</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Generic<break/>Lo</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">99.54</td>
<td align="center">15.81</td>
<td align="center">94.59–104.76</td>
<td align="center">−0.0192</td>
<td align="center">84.65–118.13</td>
<td align="center">1.24</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center" colspan="10" style="background-color:#D9D9D9"><bold>(B) C</bold><sub><bold>MAX</bold></sub></td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Reference</bold></td>
<td align="center" rowspan="2"><bold>Test</bold></td>
<td align="center" rowspan="2"><bold>C</bold><sub><bold>MAX</bold></sub> <bold>geometric mean ratio (%)</bold></td>
<td align="center" rowspan="2"><bold>Reference within-subject variability (S</bold><sub><bold>WR,</bold></sub> <bold>%)</bold></td>
<td align="center" rowspan="2"><bold>Observed 90% confidence interval</bold></td>
<td align="center" rowspan="2"><bold>Confidence bound</bold></td>
<td align="center" rowspan="2"><bold>SCABE limit</bold></td>
<td align="center" rowspan="2"><bold>Variability comparison (<xref ref-type="table-fn" rid="t004fn001"><sup>1</sup></xref>statistics of σ<sub>WT</sub>/σ<sub>WR</sub>)</bold></td>
<td align="center" colspan="2"><bold>Product approval standards</bold></td>
</tr>
<tr>
<td align="center"><bold>FDA</bold><xref ref-type="table-fn" rid="t004fn003"><sup><bold>2</bold></sup></xref></td>
<td align="center"><bold>EMA</bold><xref ref-type="table-fn" rid="t004fn004"><sup><bold>3</bold></sup></xref></td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">108.68</td>
<td align="center">22.74</td>
<td align="center">102.77–114.94</td>
<td align="center">−0.0293</td>
<td align="center">80.00–125.00</td>
<td align="center">1.46</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">109.80</td>
<td align="center">22.74</td>
<td align="center">101.06–119.29</td>
<td align="center">−0.0207</td>
<td align="center">80.00–125.00</td>
<td align="center">1.12</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Generic<break/>Hi</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">101.02</td>
<td align="center">24.72</td>
<td align="center">93.69–108.93</td>
<td align="center">−0.0469</td>
<td align="center">80.00–125.00</td>
<td align="center">1.03</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Generic<break/>Lo</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">98.99</td>
<td align="center">18.99</td>
<td align="center">91.81–106.73</td>
<td align="center">−0.0266</td>
<td align="center">81.86–122.16</td>
<td align="center">1.75</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center" colspan="10" style="background-color:#D9D9D9"><bold>(C) C</bold><sub><bold>MIN</bold></sub></td>
</tr>
<tr>
<td align="center"><bold>Reference</bold></td>
<td align="center"><bold>Test</bold></td>
<td align="center"><bold>C</bold><sub><bold>MIN</bold></sub> <bold>geometric mean ratio (%)</bold></td>
<td align="center"><bold>Reference within-subject variability (S</bold><sub><bold>WR,</bold></sub> <bold>%)</bold></td>
<td align="center"><bold>Observed 90%confidence interval</bold></td>
<td align="center"><bold>Confidence bound</bold></td>
<td align="center"><bold>SCABE limit</bold></td>
<td align="center" colspan="3"><bold>Variability comparison (<xref ref-type="table-fn" rid="t004fn002"><sup>1</sup></xref>statistics of σ<sub>WT</sub>/σ<sub>WR</sub>)</bold></td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">104.85</td>
<td align="center">12.24</td>
<td align="center">100.74–109.12</td>
<td align="center">−0.0071</td>
<td align="center">87.90–113.77</td>
<td align="center" colspan="3">1.24</td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">104.48</td>
<td align="center">12.24</td>
<td align="center">99.68–109.51</td>
<td align="center">−0.0067</td>
<td align="center">87.90–113.77</td>
<td align="center" colspan="3">1.66</td>
</tr>
<tr>
<td align="center">Generic<break/>Hi</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">99.65</td>
<td align="center">11.33</td>
<td align="center">94.81–104.73</td>
<td align="center">−0.0094</td>
<td align="center">88.75–112.68</td>
<td align="center" colspan="3">1.80</td>
</tr>
<tr>
<td align="center">Generic<break/>Lo</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">100.36</td>
<td align="center">15.14</td>
<td align="center">95.49–105.48</td>
<td align="center">−0.0177</td>
<td align="center">85.25–117.30</td>
<td align="center" colspan="3">1.01</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>EMA, European Medicines Agency; FDA, US Food and Drug Administration; <bold>σ</bold><sub>WR</sub>, within-subject standard deviation for the reference product; <bold>σ</bold><sub>WT</sub><bold>,</bold> within-subject standard deviation for the test product.</p></fn>
<fn id="t004fn002"><p><sup>1</sup>Upper limit of the 90% confidence interval of the ratio of within-subject standard deviation of test product to reference product<bold>,</bold> <bold>σ</bold><sub>WT</sub><bold>/</bold><bold>σ</bold><sub>WR</sub>.</p></fn>
<fn id="t004fn003"><p><sup>2</sup>FDA product approval standards for SCABE require the AUC and the C<sub>MAX</sub> observed 90% confidence intervals to fall within the SCABE limit.</p></fn>
<fn id="t004fn004"><p><sup>3</sup>EMA product approval standards for tacrolimus ABE require the observed 90% confidence interval to fall within 90.00%–111.10% for AUC and within 80.0%–125.0% for C<sub>MAX</sub>.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pmed.1002428.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002428.t005</object-id>
<label>Table 5</label> <caption><title>Results of bioequivalence testing using average bioequivalence (ABE) and scaled average bioequivalence (SCABE) metrics for the area under the curve (AUC) (A), maximum concentration (C<sub>max</sub>) (B), and the minimum concentration (C<sub>min</sub>) (C) in individuals with a liver transplant.</title></caption>
<alternatives>
<graphic id="pmed.1002428.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="center" colspan="10" style="background-color:#D9D9D9"><bold>(A) AUC</bold></td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Reference</bold></td>
<td align="center" rowspan="2"><bold>Test</bold></td>
<td align="center" rowspan="2"><bold>AUC geometric mean ratio (%)</bold></td>
<td align="center" rowspan="2"><bold>Reference within-subject variability (S</bold><sub><bold>WR,</bold></sub> <bold>%)</bold></td>
<td align="center" rowspan="2"><bold>Observed 90% confidence interval</bold></td>
<td align="center" rowspan="2"><bold>Confidence bound</bold></td>
<td align="center" rowspan="2"><break/><bold>SCABE limit</bold></td>
<td align="center" rowspan="2"><bold>Variability comparison (<xref ref-type="table-fn" rid="t005fn002"><sup>1</sup></xref>statistics of σ<sub>WT</sub>/σ<sub>WR</sub>)</bold></td>
<td align="center" colspan="2"><bold>Product approval standards</bold></td>
</tr>
<tr>
<td align="center">FDA<xref ref-type="table-fn" rid="t005fn003"><sup><bold>2</bold></sup></xref></td>
<td align="center">EMA<xref ref-type="table-fn" rid="t005fn004"><sup><bold>3</bold></sup></xref></td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">104.81</td>
<td align="center">14.26</td>
<td align="center">101.28–108.47</td>
<td align="center">−0.0124</td>
<td align="center">86.05–116.22</td>
<td align="center">1.34</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">107.40</td>
<td align="center">14.26</td>
<td align="center">102.88–112.12</td>
<td align="center">−0.0071</td>
<td align="center">86.05–116.22</td>
<td align="center">1.19</td>
<td align="center">Pass</td>
<td align="center">Fail</td>
</tr>
<tr>
<td align="center">Generic<break/>Hi</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">102.47</td>
<td align="center">14.26</td>
<td align="center">97.93–107.23</td>
<td align="center">−0.0142</td>
<td align="center">86.05- 116.22</td>
<td align="center">1.19</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Generic<break/>Lo</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">97.59</td>
<td align="center">12.70</td>
<td align="center">93.26–102.12</td>
<td align="center">−0.0106</td>
<td align="center">87.48–114.32</td>
<td align="center">1.50</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center" colspan="10" style="background-color:#D9D9D9"><bold>(B) C</bold><sub><bold>MAX</bold></sub></td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Reference</bold></td>
<td align="center" rowspan="2"><bold>Test</bold></td>
<td align="center" rowspan="2"><bold>C</bold><sub><bold>MAX</bold></sub> <bold>geometric mean ratio (%)</bold></td>
<td align="center" rowspan="2"><bold>Reference within-subject variability (S</bold><sub><bold>WR,</bold></sub> <bold>%)</bold></td>
<td align="center" rowspan="2"><bold>Observed 90% confidence interval</bold></td>
<td align="center" rowspan="2"><bold>Confidence bound</bold></td>
<td align="center" rowspan="2"><bold>SCABE limit</bold></td>
<td align="center" rowspan="2"><bold>Variability comparison (<xref ref-type="table-fn" rid="t005fn002"><sup>1</sup></xref>statistics of σ<sub>WT</sub>/σ<sub>WR</sub>)</bold></td>
<td align="center" colspan="2"><bold>Product approval standards</bold></td>
</tr>
<tr>
<td align="center"><bold>FDA</bold><xref ref-type="table-fn" rid="t005fn003"><sup><bold>2</bold></sup></xref></td>
<td align="center"><bold>EMA</bold><xref ref-type="table-fn" rid="t005fn004"><sup><bold>3</bold></sup></xref></td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">106.39</td>
<td align="center">17.96</td>
<td align="center">101.96–111.02</td>
<td align="center">−0.0192</td>
<td align="center">82.76–120.83</td>
<td align="center">1.83</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">111.84</td>
<td align="center">17.96</td>
<td align="center">105.98–118.03</td>
<td align="center">−0.0050</td>
<td align="center">82.76–120.83</td>
<td align="center">1.69</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Generic<break/>Hi</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">105.12</td>
<td align="center">24.61</td>
<td align="center">98.50–112.19</td>
<td align="center">−0.0424</td>
<td align="center">80.00–125.00</td>
<td align="center">1.23</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center">Generic<break/>Lo</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">95.13</td>
<td align="center">22.67</td>
<td align="center">89.14–101.52</td>
<td align="center">−0.0348</td>
<td align="center">80.00–125.00</td>
<td align="center">1.45</td>
<td align="center">Pass</td>
<td align="center">Pass</td>
</tr>
<tr>
<td align="center" colspan="10" style="background-color:#D9D9D9"><bold>(C) C</bold><sub><bold>MIN</bold></sub></td>
</tr>
<tr>
<td align="center"><bold>Reference</bold></td>
<td align="center"><bold>Test</bold></td>
<td align="center"><bold>C</bold><sub><bold>MIN</bold></sub> <bold>geometric mean ratio (%)</bold></td>
<td align="center"><bold>Reference within-subject variability (S</bold><sub><bold>WR,</bold></sub> <bold>%)</bold></td>
<td align="center"><bold>Observed 90% confidence interval</bold></td>
<td align="center"><bold>Confidence bound</bold></td>
<td align="center"><bold>SCABE limit</bold></td>
<td align="center" colspan="3"><bold>Variability comparison (<xref ref-type="table-fn" rid="t005fn002"><sup>1</sup></xref>statistics of σ<sub>WT</sub>/σ<sub>WR</sub>)</bold></td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">106.88</td>
<td align="center">12.03</td>
<td align="center">103.35–110.54</td>
<td align="center">−0.0043</td>
<td align="center">88.09–113.52</td>
<td align="center" colspan="3">1.44</td>
</tr>
<tr>
<td align="center">Innovator</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">104.64</td>
<td align="center">12.03</td>
<td align="center">100.89–108.54</td>
<td align="center">−0.0074</td>
<td align="center">88.09–113.52</td>
<td align="center" colspan="3">1.09</td>
</tr>
<tr>
<td align="center">Generic<break/>Hi</td>
<td align="center">Generic<break/>Lo</td>
<td align="center">97.91</td>
<td align="center">12.94</td>
<td align="center">93.96–102.03</td>
<td align="center">−0.0118</td>
<td align="center">87.25–114.61</td>
<td align="center" colspan="3">1.02</td>
</tr>
<tr>
<td align="center">Generic<break/>Lo</td>
<td align="center">Generic<break/>Hi</td>
<td align="center">102.14</td>
<td align="center">9.84</td>
<td align="center">98.02–106.43</td>
<td align="center">−0.0057</td>
<td align="center">90.15–110.93</td>
<td align="center" colspan="3">1.76</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>EMA, European Medicines Agency; FDA, US Food and Drug Administration; <bold>σ</bold><sub>WR</sub>, within-subject standard deviation for the reference product; <bold>σ</bold><sub>WT</sub>, within-subject standard deviation for the test product.</p></fn>
<fn id="t005fn002"><p><sup>1</sup>Upper limit of the 90% confidence interval of the ratio of within-subject standard deviation of test product to reference product<bold>,</bold> <bold>σ</bold><sub>WT</sub><bold>/</bold><bold>σ</bold><sub>WR</sub>.</p></fn>
<fn id="t005fn003"><p><sup>2</sup>FDA product approval standards for SCABE require the AUC and the C<sub>MAX</sub> observed 90% confidence intervals to fall within the SCABE limit.</p></fn>
<fn id="t005fn004"><p><sup>3</sup>EMA product approval standards for tacrolimus ABE require the observed 90% confidence interval to fall within 90.00%–111.10% for AUC and within 80.0%–125.0% for C<sub>MAX.</sub></p></fn>
</table-wrap-foot>
</table-wrap>
<p>Individual pharmacokinetic tacrolimus time-concentration curves for each pharmacokinetic period by product are presented (Figs D and E in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>) [<xref ref-type="bibr" rid="pmed.1002428.ref039">39</xref>]. Upon visual inspection of individual pharmacokinetic curves, differences can be observed upon comparison between products and between replicate administration of the same product.</p>
</sec>
<sec id="sec019">
<title>Subgroup analysis</title>
<p>The study was not powered to show a difference by any subgroup analyzed. A majority of individuals with a kidney transplant were genotyped as nonexpressers with CYP3A5 *3/*3 (<italic>n</italic> = 23), and 12 were expressers carrying *1/*3 (<italic>n</italic> = 10), and *1/*1(<italic>n</italic> = 2) variants (Figs F and G in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>). Most individuals with a liver transplant were genotyped as nonexpressers (<italic>n</italic> = 30); however, 6 expressed the *1/*3 variant (Figs H and I in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>). Donor samples were available for 17 individuals with a kidney transplant and for 24 with a liver transplant. Most kidney donors were genotyped as nonexpressers (<italic>n</italic> = 12); however, 5 were expressers with *1/*3 (<italic>n</italic> = 4) and *1/*1 (<italic>n</italic> = 1) variants (Figs J and K in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>). Most liver individual donors were genotyped as CYP3A5 nonexpressers (<italic>n</italic> = 14); however, 10 were expressers with *1/*3 (<italic>n</italic> = 5) and *1/*1 (<italic>n</italic> = 5) variants (Figs L and M in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>).</p>
<p>Individuals with a kidney transplant expressing CYP3A5 required significantly higher tacrolimus doses to achieve target tacrolimus trough blood levels (8.17 ± 2.5 versus 4.26 ± 1.9 mg/day [<italic>p</italic> = 0.0002]). In individuals with a liver transplant, recipient CYP3A5 genotype had no effect on the tacrolimus doses required to achieve target trough blood levels (4.67 ± 2.2 versus 4.5 ± 1.2 mg/day [<italic>p</italic> = 0.80]). When assessing the donor variant status, donor CYP3A5 expression had no impact on tacrolimus dose requirements for either individuals with a kidney transplant (6.25 ± 2.1 versus 5.40 ± 4.2 mg/day [<italic>p</italic> = 0.69]) or those with a liver transplant (4.71 ± 1.9 versus 5.70 ± 2.4 mg/day [<italic>p</italic> = 0.29]). No differences in within-subject variability were observed by CYP3A5 genotype in individuals with a kidney or liver transplant. No association between AUC and ABCB1 genotype as well as no impact on dosing requirements for individuals with a kidney (ANOVA <italic>p</italic> = 0.08) or liver transplant (ANOVA <italic>p</italic> = 0.35) was found (Figs N and O in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref> for AUCs).</p>
<p>ABE and SCABE limits for AUC were calculated for subgroups to assess for consistency of results (Figs PA–PC in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref> [kidney] and Figs QA–QC in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref> [liver]). In general, all FDA ABE limits were met, with most also meeting the stricter SCABE limits; however, most exceeded the EMA upper limit of 111.11%. For subgroups not meeting the ABE or SCABE criteria, the number of observations was 10 or fewer, resulting in low statistical power to conclude ABE or SCABE, except for POR*28. ABE was concluded for both POR*28 carriers and noncarriers for individuals with a kidney or liver transplant. For POR*28 carriers, SCABE was demonstrated except in the case of Generic Lo versus Innovator in individuals with a kidney transplant (<italic>n</italic> = 17) and Generic Hi versus Generic Lo in individuals with a liver transplant (<italic>n</italic> = 17). For POR*28 noncarriers, SCABE was demonstrated except for Generic Hi versus Innovator in individuals with a kidney transplant (<italic>n</italic> = 18) and individuals with a liver transplant (<italic>n</italic> = 19) and for Generic Lo versus Innovator in individuals with a liver transplant (<italic>n</italic> = 19). ABE criteria were met for most subgroups, except for individuals with a kidney transplant and a CYP3A4*1B genotype and individuals with a liver transplant and a CYP3A5 *1/*1 or *1/*3 genotype (Figs PA-C in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref> [kidney], Figs QA–C in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref> [liver]).</p>
</sec>
<sec id="sec020">
<title>Tacrolimus metabolite exposure</title>
<p>The blood concentrations of the major tacrolimus metabolite, 13-O-desmethyl tacrolimus, were also found to meet FDA ABE and SCABE AUC bioequivalence acceptance criteria in individuals with a kidney or liver transplant, but they failed EMA AUC acceptance limits (Tables T–U in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>).</p>
</sec>
<sec id="sec021">
<title>Safety</title>
<p>One serious adverse event of pyelonephritis was reported in an individual with a kidney transplant, resulting in hospitalization prior to study drug administration. This event resolved with treatment, and the individual was withdrawn. Fifty-two percent and 65% of all individuals with a kidney or liver transplant, respectively, reported an adverse event. The adverse events are sorted by formulation and by individuals with a kidney or liver transplant and CTCAE disorder classification. The Exact McNemar test for paired categorical data with adjustments for multiple comparisons was used to compare adverse event rates among the products. No statistically significant differences among any pairs of products were found for any adverse event code or for adverse events overall (Table V in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>).</p>
<p>No acute rejections occurred during the study period of 6 weeks. Baseline and weekly assessments included markers of transplant function in individuals with a kidney (creatinine) or liver (AST, ALT, and alkaline phosphatase) transplant. To compare kidney and liver function tests among products, a mixed effects model was run with a term designating the product received in each period and a random subject term and using the Tukey HSD test for multiple comparisons, where needed. No statistically significant differences were found among products (Fig R–W in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>).</p>
</sec>
</sec>
<sec id="sec022" sec-type="conclusions">
<title>Discussion</title>
<p>Public concerns remain regarding generic tacrolimus use in individuals with a kidney or liver transplant despite the significant market penetration of generic tacrolimus in the US. Historically, concerns were generated by a lack of definitive clinical evidence with properly controlled trials in target populations [<xref ref-type="bibr" rid="pmed.1002428.ref013">13</xref>]. Limitations of previous studies [<xref ref-type="bibr" rid="pmed.1002428.ref040">40</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref045">45</xref>] include retrospective evaluations, case reports, poor study design (underpowered or without appropriate controls), analysis of trough concentrations only, lack of analysis of confounders such as comedications and comorbidities, incorrect pharmacokinetic analysis, and use of nonspecific immunoassays in which metabolites may interfere with tacrolimus concentration measurements, thus leading to considerable bias and limited conclusions [<xref ref-type="bibr" rid="pmed.1002428.ref013">13</xref>].</p>
<p>The present randomized, prospective, 3-treatment, 6-period, crossover, replicate-dosing study in stable individuals with a kidney or liver transplant systematically addresses the aforementioned public concerns regarding generic tacrolimus. The replicate dosing study design allowed the analysis of tacrolimus products using the tighter SCABE standards required by the FDA for NTI drugs. Clinically, the present study represents a scenario in which an individual with a kidney or liver transplant is randomly switched between 3 tacrolimus products every week for 6 weeks. The pharmacokinetic parameters (AUC and C<sub>max</sub>) demonstrated bioequivalence by SCABE criteria, implying similar tacrolimus exposure is achieved when individuals with a kidney or liver transplant are switched between these tacrolimus products. Although not required for bioequivalence testing, C<sub>min</sub> also met the SCABE criteria.</p>
<p>These results support a previous prospective, multicenter, open-label, randomized, 2-period, crossover, pharmacokinetic study comparing twice-daily generic tacrolimus (Sandoz) versus reference tacrolimus (Prograf) in stable kidney transplant recipients [<xref ref-type="bibr" rid="pmed.1002428.ref030">30</xref>]. In 68 kidney transplant recipients, there were no significant differences in AUC C<sub>0</sub>, C<sub>max</sub>, or T<sub>max</sub> between the generic and reference products, resulting in ratios of the geometric mean and 90% CI for AUC and C<sub>max</sub> that were reported as 102% (97%–108%) and 109% (101%–118%), respectively [<xref ref-type="bibr" rid="pmed.1002428.ref046">46</xref>]. Post hoc analysis revealed the products also met SCABE acceptance criteria [<xref ref-type="bibr" rid="pmed.1002428.ref047">47</xref>]. In contrast to the present study, the latter did not include comparisons to other generic tacrolimus products or the comparison of 2 generics, and liver transplant recipients and relevant genetic polymorphisms were not analyzed.</p>
<p>Pharmacogenomic profiling of individuals was performed, specifically, genotyping of CYP3A5 polymorphisms to identify the “poor absorber” [<xref ref-type="bibr" rid="pmed.1002428.ref020">20</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref023">23</xref>]. The genetic polymorphisms most important for tacrolimus pharmacokinetics were assessed and, in general, had no effect on bioequivalence. The only exceptions were that bioequivalence of tacrolimus AUC was not found for individuals with a kidney transplant expressing CYP3A4*1B and individuals with a liver transplant expressing CYP3A5, but this analysis was underpowered for said subgroups. Moreover, an influence of POR*28 polymorphism on bioequivalence using SCABE metrics could not be excluded, although ABE criteria were met. Dosing differences by genotype were similar across products [<xref ref-type="bibr" rid="pmed.1002428.ref048">48</xref>]. The major tacrolimus metabolite concentrations were bioequivalent for AUC. In contrast to tacrolimus, 13-O-desmethy tacrolimus is not directly administered but formed from tacrolimus, mostly by intestinal and liver cytochrome P4503A enzymes. Thus, its formation is greatly influenced by the aforementioned polymorphisms and its pharmacokinetics more variable than that of tacrolimus.</p>
<p>In this study, the 2 tacrolimus generic products met US FDA SCABE criteria when compared to the innovator product and with each other in individuals after a kidney or liver transplant. However, when applying the more rigid EMA criteria, the Generic Lo product failed AUC testing when compared to Innovator in individuals receiving a kidney or liver transplant. The EMA requires a narrow 90% confidence interval contained within the confidence limits of 90.00%–111.11% acceptance criterion for AUC, but not for C<sub>max</sub>, for which the usual 80.00%–125.00% acceptance limit applies [<xref ref-type="bibr" rid="pmed.1002428.ref014">14</xref>]. As shown in <xref ref-type="table" rid="pmed.1002428.t004">Table 4</xref>, in general these acceptance criteria were met, with the only exception being that of Innovator versus Generic Lo, for which the upper limits of the 90% confidence intervals—111.30% (kidney) and 112.11% (liver)—were slightly above the upper EMA acceptance criterion for AUC. The conflicting approval guidelines lead to different interpretations of the bioequivalence data of the same study. In this context, it should be considered that the EMA and Health Canada bioequivalence limits for NTI drugs were set with single-dose healthy volunteer studies in mind, a population that is inherently less variable than individuals receiving a transplant after multiple doses [<xref ref-type="bibr" rid="pmed.1002428.ref004">4</xref>]. While the FDA SCABE limits adjust based on the pharmacokinetic variability of the innovator in the study population, the EMA and Health Canada bioequivalence limits for NTI drugs are fixed, which explains the different conclusions when FDA, EMA, or Health Canada limits are employed. This study highlights the need for global harmonization of bioequivalence approval standards of NTI drugs to prevent different interpretations of bioequivalence study results.</p>
<p>Individual pharmacokinetic time concentration curves for all products are provided in Section C in <xref ref-type="supplementary-material" rid="pmed.1002428.s005">S2 Appendix</xref>. These data visually depict the intraindividual variability that can be observed within the same product despite administering the same lot at the same dose in a controlled setting. Such observed intraindividual variability led the FDA to require repeat crossover study designs for NTI drugs, which requires that each individual receives each of the tested products twice to assess and to compare intraindividual variability between tacrolimus innovator and generic products. Upon visual inspection of individual pharmacokinetic curves, differences can be observed between products and between replicate administration of the same product.</p>
<p>Safety was similar across products over the observation period of 6 weeks. Although we did not evaluate the long-term impact of generic tacrolimus on acute rejection and graft survival, this study evaluates pharmacokinetic parameters as a surrogate for safety exposure.</p>
<p>Several design elements strengthen the findings, such as validated, specific, and sensitive high-performance liquid chromatography (HPLC)-tandem mass spectrometry analysis of tacrolimus and metabolites, quality control of the tacrolimus test batches, independent parallel analysis by the study team and the FDA, genotypic analysis of individuals donating or receiving a kidney or liver transplant, and close adherence monitoring using a combination of diaries, MEMS caps, and pill counts. Finally, this study was adequately powered to assess bioequivalence in both kidney and liver transplant recipients. However, our study also had certain limitations. A differential carryover or sequence effect cannot be fully excluded, even though we did not detect any statistically significant sequence effects in statistical modeling. When considering the half-life of immediate-release tacrolimus and the length of the treatment period, this effect is unlikely to occur. The pharmacokinetic profiling occurred in strictly controlled conditions with recipients who were highly adherent, which did not allow the evaluation about the impact of nonadherence or the impact of feeding on possible pharmacokinetic differences between products. The study design also did not allow for assessment of the potential impact of differing appearances of the 3 tacrolimus products on adherence. The safety data should be interpreted cautiously in the light of the small number of participants and short observation periods. Lastly, only the 1 mg tacrolimus dosage strength was utilized, limiting generalizability to the 0.5 mg and 5 mg dosage strengths; however, the 1 mg capsule is the most common clinically utilized dosage strength.</p>
<p>The present study was specifically designed to address lingering concerns in the transplant community [<xref ref-type="bibr" rid="pmed.1002428.ref008">8</xref>–<xref ref-type="bibr" rid="pmed.1002428.ref011">11</xref>]. While typical single-dose healthy volunteer bioequivalence studies mainly assess prescribability, our study in steady-state, stable individuals with a kidney or liver transplant mainly assessed the more important switchability between innovator and generics and between generics [<xref ref-type="bibr" rid="pmed.1002428.ref005">5</xref>,<xref ref-type="bibr" rid="pmed.1002428.ref006">6</xref>]. The present study suggests that tacrolimus and the tested generic products in healthy volunteers were also bioequivalent in individuals with a kidney or liver transplant. Moreover, the generics were bioequivalent to each other. Even the tighter FDA SCABE criteria were met, and there was no difference between the different tacrolimus products in terms of within-subject variability.</p>
</sec>
<sec id="sec023">
<title>Supporting information</title>
<supplementary-material id="pmed.1002428.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.s001" xlink:type="simple">
<label>S1 Consort Checklist</label>
<caption>
<title>Consolidated Standards Of Reporting Trials (CONSORT) checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002428.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.s002" xlink:type="simple">
<label>S1 Text</label>
<caption>
<title>Trial protocol.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002428.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.s003" xlink:type="simple">
<label>S2 Text</label>
<caption>
<title>Statistical analysis plan.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002428.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.s004" xlink:type="simple">
<label>S1 Appendix</label>
<caption>
<title>Supporting information methods.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002428.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002428.s005" xlink:type="simple">
<label>S2 Appendix</label>
<caption>
<title>Supporting information results.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We would like to thank the individuals receiving a kidney or liver transplant and their families for their willingness to participate in this study.</p>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>ABE</term>
<def><p>average bioequivalence</p></def>
</def-item>
<def-item><term>ALT</term>
<def><p>alanine aminotransferase</p></def>
</def-item>
<def-item><term>ANDA</term>
<def><p>Abbreviated New Drug Application</p></def>
</def-item>
<def-item><term>AST</term>
<def><p>aspartate aminotransferase</p></def>
</def-item>
<def-item><term>AUC</term>
<def><p>area under the curve</p></def>
</def-item>
<def-item><term>C<sub>max</sub></term>
<def><p>maximum concentration</p></def>
</def-item>
<def-item><term>C<sub>min</sub></term>
<def><p>minimum concentration</p></def>
</def-item>
<def-item><term>CONSORT</term>
<def><p>Consolidated Standards Of Reporting Trials</p></def>
</def-item>
<def-item><term>CTCAE</term>
<def><p>Common Terminology Criteria for Adverse Events</p></def>
</def-item>
<def-item><term>CYP</term>
<def><p>cytochrome</p></def>
</def-item>
<def-item><term>EMA</term>
<def><p>European Medicines Agency</p></def>
</def-item>
<def-item><term>FDA</term>
<def><p>United States Food and Drug Administration</p></def>
</def-item>
<def-item><term>HPLC</term>
<def><p>high-performance liquid chromatography</p></def>
</def-item>
<def-item><term>HSD</term>
<def><p>honest significant difference</p></def>
</def-item>
<def-item><term>MEMS</term>
<def><p>Medication Event Monitoring System</p></def>
</def-item>
<def-item><term>NTI</term>
<def><p>narrow therapeutic index</p></def>
</def-item>
<def-item><term>PK</term>
<def><p>pharmacokinetics</p></def>
</def-item>
<def-item><term>Reference</term>
<def><p>tacrolimus product that is used as reference product for analysis</p></def>
</def-item>
<def-item><term>SCABE</term>
<def><p>scaled average bioequivalence</p></def>
</def-item>
<def-item><term>T<sub>max</sub></term>
<def><p>time-to-maximum concentration</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pmed.1002428.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ensor</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Trofe-Clark</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gabardi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>McDevitt-Potter</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Shullo</surname> <given-names>MA</given-names></name>. <article-title>Generic maintenance immunosuppression in solid organ transplant recipients</article-title>. <source>Pharmacotherapy</source>. <year>2011</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1111</fpage>–<lpage>29</lpage>. Epub 2011/10/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1592/phco.31.11.1111" xlink:type="simple">10.1592/phco.31.11.1111</ext-link></comment> <object-id pub-id-type="pmid">22026398</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref002"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">O’Neil J. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Congressional Budget Office 1988 [cited 2012 May 29]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/DOCKETS/dailys/04/June04/061404/03p-0029-bkg0001-Ref-15-vol3.pdf" xlink:type="simple">http://www.fda.gov/ohrms/DOCKETS/dailys/04/June04/061404/03p-0029-bkg0001-Ref-15-vol3.pdf</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sellares</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>de Freitas</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Mengel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Reeve</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Einecke</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Sis</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence</article-title>. <source>Am J Transplant</source>. <year>2012</year>;<volume>12</volume>(<issue>2</issue>):<fpage>388</fpage>–<lpage>99</lpage>. Epub 2011/11/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-6143.2011.03840.x" xlink:type="simple">10.1111/j.1600-6143.2011.03840.x</ext-link></comment> <object-id pub-id-type="pmid">22081892</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Davit</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Nwakama</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Buehler</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Conner</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Haidar</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>DT</given-names></name>, <etal>et al</etal>. <article-title>Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration</article-title>. <source>Ann Pharmacother</source>. <year>2009</year>;<volume>43</volume>(<issue>10</issue>):<fpage>1583</fpage>–<lpage>97</lpage>. Epub 2009/09/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1345/aph.1M141" xlink:type="simple">10.1345/aph.1M141</ext-link></comment> <object-id pub-id-type="pmid">19776300</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Christians</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Klawitter</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Clavijo</surname> <given-names>CF</given-names></name>. <article-title>Bioequivalence testing of immunosuppressants: concepts and misconceptions</article-title>. <source>Kidney Int Suppl</source>. <year>2010</year>;(<issue>115</issue>):<fpage>S1</fpage>–<lpage>7</lpage>. Epub 2010/02/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ki.2009.504" xlink:type="simple">10.1038/ki.2009.504</ext-link></comment> <object-id pub-id-type="pmid">20150904</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hauck</surname> <given-names>WW</given-names></name>, <name name-style="western"><surname>Anderson</surname> <given-names>S</given-names></name>. <article-title>Measuring switchability and prescribability: when is average bioequivalence sufficient?</article-title> <source>J Pharmacokinet Biopharm</source>. <year>1994</year>;<volume>22</volume>(<issue>6</issue>):<fpage>551</fpage>–<lpage>64</lpage>. Epub 1994/12/01. <object-id pub-id-type="pmid">7473081</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pollard</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nashan</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Johnston</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hoyer</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Belitsky</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Keown</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001</article-title>. <source>Clin Ther</source>. <year>2003</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1654</fpage>–<lpage>69</lpage>. Epub 2003/07/16. <object-id pub-id-type="pmid">12860490</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alloway</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Isaacs</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lake</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hoyer</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>First</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Helderman</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants</article-title>. <source>Am J Transplant</source>. <year>2003</year>;<volume>3</volume>(<issue>10</issue>):<fpage>1211</fpage>–<lpage>5</lpage>. Epub 2003/09/27. <object-id pub-id-type="pmid">14510694</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harrison</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Schiff</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Coursol</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Daley</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Dipchand</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Heywood</surname> <given-names>NM</given-names></name>, <etal>et al</etal>. <article-title>Generic immunosuppression in solid organ transplantation: a Canadian perspective</article-title>. <source>Transplantation</source>. <year>2012</year>;<volume>93</volume>(<issue>7</issue>):<fpage>657</fpage>–<lpage>65</lpage>. Epub 2012/01/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/TP.0b013e3182445e9d" xlink:type="simple">10.1097/TP.0b013e3182445e9d</ext-link></comment> <object-id pub-id-type="pmid">22267158</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Gelder</surname> <given-names>T</given-names></name>. <article-title>European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs</article-title>. <source>Transpl Int</source>. <year>2011</year>;<volume>24</volume>(<issue>12</issue>):<fpage>1135</fpage>–<lpage>41</lpage>. Epub 2011/10/29. 10.1111/j.1432-2277.2011.01378.x. 22032583. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1432-2277.2011.01378.x" xlink:type="simple">10.1111/j.1432-2277.2011.01378.x</ext-link></comment> <object-id pub-id-type="pmid">22032583</object-id></mixed-citation></ref>
<ref id="pmed.1002428.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Uber</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Zuckermann</surname> <given-names>AO</given-names></name>, <name name-style="western"><surname>Sweet</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Corris</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>McNeil</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory</article-title>. <source>J Heart Lung Transplant</source>. <year>2009</year>;<volume>28</volume>(<issue>7</issue>):<fpage>655</fpage>–<lpage>60</lpage>. Epub 2009/06/30. 10.1016/j.healun.2009.05.001. 19560691. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.healun.2009.05.001" xlink:type="simple">10.1016/j.healun.2009.05.001</ext-link></comment> <object-id pub-id-type="pmid">19560691</object-id></mixed-citation></ref>
<ref id="pmed.1002428.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klintmalm</surname> <given-names>GB</given-names></name>. <article-title>Immunosuppression, generic drugs and the FDA</article-title>. <source>Am J Transplant</source>. <year>2011</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1765</fpage>–<lpage>6</lpage>. Epub 2011/07/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-6143.2011.03616.x" xlink:type="simple">10.1111/j.1600-6143.2011.03616.x</ext-link></comment> <object-id pub-id-type="pmid">21794082</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Molnar</surname> <given-names>AO</given-names></name>, <name name-style="western"><surname>Fergusson</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Tsampalieros</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Bennett</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fergusson</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ramsay</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis</article-title>. <source>BMJ</source>. <year>2015</year>;<volume>350</volume>:<fpage>h3163</fpage>. Epub 2015/06/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.h3163" xlink:type="simple">10.1136/bmj.h3163</ext-link></comment> <object-id pub-id-type="pmid">26101226</object-id>; PubMed Central PMCID: PMCPMC4476317.</mixed-citation></ref>
<ref id="pmed.1002428.ref014"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency. European Medicines Agency. Guideline on the Investigation of Bioequivalence London, UK2010 [cited 2016 October 26]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf" xlink:type="simple">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref015"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Health Canada. Guidance Document—Comparative Bioavailability Standards: Formulations Used for Systemic Effects Ottawa, Ontario: Health Canada; 2012 [cited 2016 October 26]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/bio/gd_standards_ld_normes-eng.pdf" xlink:type="simple">http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/bio/gd_standards_ld_normes-eng.pdf</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref016"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Food and Drug Administration. Draft Guidance on Tacrolimus 2014 [cited 2015 December 2]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM406344.pdf" xlink:type="simple">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM406344.pdf</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yu</surname> <given-names>LX</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Lionberger</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Makhlouf</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Schuirmann</surname> <given-names>DJ</given-names></name>, <etal>et al</etal>. <article-title>Novel bioequivalence approach for narrow therapeutic index drugs</article-title>. <source>Clin Pharmacol Ther</source>. <year>2015</year>;<volume>97</volume>(<issue>3</issue>):<fpage>286</fpage>–<lpage>91</lpage>. Epub 2015/02/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cpt.28" xlink:type="simple">10.1002/cpt.28</ext-link></comment> <object-id pub-id-type="pmid">25669762</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Birdwell</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Decker</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Barbarino</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Peterson</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Stein</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Sadee</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing</article-title>. <source>Clin Pharmacol Ther</source>. <year>2015</year>;<volume>98</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>24</lpage>. Epub 2015/03/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cpt.113" xlink:type="simple">10.1002/cpt.113</ext-link></comment> <object-id pub-id-type="pmid">25801146</object-id>; PubMed Central PMCID: PMCPMC4481158.</mixed-citation></ref>
<ref id="pmed.1002428.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Picard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Bergan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Marquet</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>van Gelder</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Wallemacq</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Hesselink</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs</article-title>. <source>Ther Drug Monit</source>. <year>2016</year>;<volume>38</volume> <issue>Suppl 1</issue>:<fpage>S57</fpage>–<lpage>69</lpage>. Epub 2015/10/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/ftd.0000000000000255" xlink:type="simple">10.1097/ftd.0000000000000255</ext-link></comment> <object-id pub-id-type="pmid">26469711</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kuypers</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>de Jonge</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Naesens</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lerut</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Verbeke</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Vanrenterghem</surname> <given-names>Y</given-names></name>. <article-title>CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients</article-title>. <source>Clin Pharmacol Ther</source>. <year>2007</year>;<volume>82</volume>(<issue>6</issue>):<fpage>711</fpage>–<lpage>25</lpage>. Epub 2007/05/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.clpt.6100216" xlink:type="simple">10.1038/sj.clpt.6100216</ext-link></comment> <object-id pub-id-type="pmid">17495880</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pallet</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Jannot</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>El Bahri</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Etienne</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Buchler</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>de Ligny</surname> <given-names>BH</given-names></name>, <etal>et al</etal>. <article-title>Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations</article-title>. <source>Am J Transplant</source>. <year>2015</year>;<volume>15</volume>(<issue>3</issue>):<fpage>800</fpage>–<lpage>5</lpage>. Epub 2015/01/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ajt.13059" xlink:type="simple">10.1111/ajt.13059</ext-link></comment> <object-id pub-id-type="pmid">25588704</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elens</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Hesselink</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Bouamar</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Budde</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>de Fijter</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>De Meyer</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients</article-title>. <source>Ther Drug Monit</source>. <year>2014</year>;<volume>36</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>9</lpage>. Epub 2013/09/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/FTD.0b013e31829da6dd" xlink:type="simple">10.1097/FTD.0b013e31829da6dd</ext-link></comment> <object-id pub-id-type="pmid">24061445</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stefanovic</surname> <given-names>NZ</given-names></name>, <name name-style="western"><surname>Cvetkovic</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Jevtovic-Stoimenov</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Ignjatovic</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Paunovic</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Velickovic</surname> <given-names>RM</given-names></name>. <article-title>Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function</article-title>. <source>Exp Ther Med</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>1149</fpage>–<lpage>56</lpage>. Epub 2015/12/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3892/etm.2015.2598" xlink:type="simple">10.3892/etm.2015.2598</ext-link></comment> <object-id pub-id-type="pmid">26622455</object-id>; PubMed Central PMCID: PMCPMC4533232.</mixed-citation></ref>
<ref id="pmed.1002428.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Christians</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Jacobsen</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Benet</surname> <given-names>LZ</given-names></name>, <name name-style="western"><surname>Lampen</surname> <given-names>A</given-names></name>. <article-title>Mechanisms of clinically relevant drug interactions associated with tacrolimus</article-title>. <source>Clin Pharmacokinet</source>. <year>2002</year>;<volume>41</volume>(<issue>11</issue>):<fpage>813</fpage>–<lpage>51</lpage>. Epub 2002/08/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/00003088-200241110-00003" xlink:type="simple">10.2165/00003088-200241110-00003</ext-link></comment> <object-id pub-id-type="pmid">12190331</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref025"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Food and Drug Administration. Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations 2015 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/scripts/cder/ob/docs/queryai.cfm" xlink:type="simple">http://www.accessdata.fda.gov/scripts/cder/ob/docs/queryai.cfm</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref026"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Sandoz Tacrolimus Abbreviated New Drug Application Number A065461 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=065461" xlink:type="simple">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=065461</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref027"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Dr Reddy Tacrolimus Abbreviated New Drug Application Number A090509 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=090509" xlink:type="simple">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=090509</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref028"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mylan Tacrolimus Abbreviated New Drug Application Number A090596 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=090596" xlink:type="simple">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=090596</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref029"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Accord Tacrolimus Abbreviated New Drug Application Number A091195 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=091195" xlink:type="simple">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=091195</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref030"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Panacea Tacrolimus Abbreviated New Drug Application Number A09082 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=090802" xlink:type="simple">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=090802</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref031"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Convention United SP. Tacrolimus Revision Bulletin, April 1, 2013 Rockville, MD2013 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/revisions/tacrolimus_capsulesm.pdf" xlink:type="simple">http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/revisions/tacrolimus_capsulesm.pdf</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harris</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Taylor</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Thielke</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Payne</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gonzalez</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Conde</surname> <given-names>JG</given-names></name>. <article-title>Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support</article-title>. <source>Journal of biomedical informatics</source>. <year>2009</year>;<volume>42</volume>(<issue>2</issue>):<fpage>377</fpage>–<lpage>81</lpage>. Epub 2008/10/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jbi.2008.08.010" xlink:type="simple">10.1016/j.jbi.2008.08.010</ext-link></comment> <object-id pub-id-type="pmid">18929686</object-id>; PubMed Central PMCID: PMCPMC2700030.</mixed-citation></ref>
<ref id="pmed.1002428.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diletti</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hauschke</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Steinijans</surname> <given-names>VW</given-names></name>. <article-title>Sample size determination for bioequivalence assessment by means of confidence intervals</article-title>. <source>Int J Clin Pharmacol Ther Toxicol</source>. <year>1992</year>;<volume>30</volume> <issue>Suppl 1</issue>:<fpage>S51</fpage>–<lpage>8</lpage>. Epub 1992/01/01. <object-id pub-id-type="pmid">1601532</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref034"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Administration FAD. Food And Drug Administration. Guidance for Industry—Statistical Approaches to Establishing Bioequivalence Rockville, MD2001 [cited 2012 June 7]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/drugs/guidances/ucm070244.pdf" xlink:type="simple">https://www.fda.gov/downloads/drugs/guidances/ucm070244.pdf</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref035"><label>35</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Montgomery</surname> <given-names>DC</given-names></name>. <chapter-title>Design and Analysis of Experiments</chapter-title>. <edition>1st ed.</edition> <publisher-name>Wiley</publisher-name>. <year>2013</year>.</mixed-citation></ref>
<ref id="pmed.1002428.ref036"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">National Cancer Instiute. Common Toxicty Criteria for Adverse Events, v 4.0 2010 [cited 2015 December 1]. Available from: <ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_4_with_lay_terms.pdf" xlink:type="simple">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_4_with_lay_terms.pdf</ext-link></mixed-citation></ref>
<ref id="pmed.1002428.ref037"><label>37</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Agresti</surname> <given-names>A.</given-names></name> <source>Categorical Data Analysis (PDF)</source>. <publisher-loc>Hooken, New Jersey</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name> <year>2002</year>. ISBN 0-471-36093-7</mixed-citation></ref>
<ref id="pmed.1002428.ref038"><label>38</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Daniel</surname> <given-names>WW</given-names></name>. <chapter-title>Kruskal–Wallis one-way analysis of variance by ranks</chapter-title>. <source>Applied Nonparametric Statistics</source>. <edition>2nd ed.</edition> <publisher-loc>Boston</publisher-loc>: <publisher-name>PWS-Kent</publisher-name>. pp. <fpage>226</fpage>–<lpage>234</lpage>. <year>1990</year>. ISBN 0-534-91976-6</mixed-citation></ref>
<ref id="pmed.1002428.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sauter</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Steinijans</surname> <given-names>VW</given-names></name>, <name name-style="western"><surname>Diletti</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Bohm</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schulz</surname> <given-names>HU</given-names></name>. <article-title>Presentation of results from bioequivalence studies</article-title>. <source>Int J Clin Pharmacol Ther Toxicol</source>. <year>1992</year>;<volume>30</volume>(<issue>7</issue>):<fpage>233</fpage>–<lpage>56</lpage>. Epub 1992/07/01. <object-id pub-id-type="pmid">1506127</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Duong</surname> <given-names>SQ</given-names></name>, <name name-style="western"><surname>Lal</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Joshi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Feingold</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Venkataramanan</surname> <given-names>R</given-names></name>. <article-title>Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients</article-title>. <source>Pediatr Transplant</source>. <year>2015</year>;<volume>19</volume>(<issue>8</issue>):<fpage>911</fpage>–<lpage>7</lpage>. Epub 2015/10/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/petr.12608" xlink:type="simple">10.1111/petr.12608</ext-link></comment> <object-id pub-id-type="pmid">26497983</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Robertsen</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Asberg</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ingero</surname> <given-names>AO</given-names></name>, <name name-style="western"><surname>Vethe</surname> <given-names>NT</given-names></name>, <name name-style="western"><surname>Bremer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bergan</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed</article-title>. <source>Transplantation</source>. <year>2015</year>;<volume>99</volume>(<issue>3</issue>):<fpage>528</fpage>–<lpage>32</lpage>. Epub 2014/08/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/TP.0000000000000384" xlink:type="simple">10.1097/TP.0000000000000384</ext-link></comment> <object-id pub-id-type="pmid">25148382</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Min</surname> <given-names>SI</given-names></name>, <name name-style="western"><surname>Ha</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Ahn</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>DD</given-names></name>, <etal>et al</etal>. <article-title>Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients</article-title>. <source>Nephrol Dial Transplant</source>. <year>2013</year>;<volume>28</volume>(<issue>12</issue>):<fpage>3110</fpage>–<lpage>9</lpage>. Epub 2013/10/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ndt/gft300" xlink:type="simple">10.1093/ndt/gft300</ext-link></comment> <object-id pub-id-type="pmid">24084327</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spence</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Hui</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>J</given-names></name>. <article-title>Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system</article-title>. <source>Pharmacotherapy</source>. <year>2012</year>;<volume>32</volume>(<issue>11</issue>):<fpage>981</fpage>–<lpage>7</lpage>. Epub 2012/10/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/phar.1130" xlink:type="simple">10.1002/phar.1130</ext-link></comment> <object-id pub-id-type="pmid">23074134</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Momper</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Ridenour</surname> <given-names>TA</given-names></name>, <name name-style="western"><surname>Schonder</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Shapiro</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Humar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Venkataramanan</surname> <given-names>R</given-names></name>. <article-title>The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function</article-title>. <source>Am J Transplant</source>. <year>2011</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1861</fpage>–<lpage>7</lpage>. Epub 2011/07/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-6143.2011.03615.x" xlink:type="simple">10.1111/j.1600-6143.2011.03615.x</ext-link></comment> <object-id pub-id-type="pmid">21714845</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McDevitt-Potter</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Sadaka</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Tichy</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Rogers</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Gabardi</surname> <given-names>S</given-names></name>. <article-title>A multicenter experience with generic tacrolimus conversion</article-title>. <source>Transplantation</source>. <year>2011</year>;<volume>92</volume>(<issue>6</issue>):<fpage>653</fpage>–<lpage>7</lpage>. Epub 2011/07/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/TP.0b013e31822a79ad" xlink:type="simple">10.1097/TP.0b013e31822a79ad</ext-link></comment> <object-id pub-id-type="pmid">21788920</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alloway</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Sadaka</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Trofe-Clark</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wiland</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bloom</surname> <given-names>RD</given-names></name>. <article-title>A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients</article-title>. <source>Am J Transplant</source>. <year>2012</year>;<volume>12</volume>(<issue>10</issue>):<fpage>2825</fpage>–<lpage>31</lpage>. Epub 2012/07/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-6143.2012.04174.x" xlink:type="simple">10.1111/j.1600-6143.2012.04174.x</ext-link></comment> <object-id pub-id-type="pmid">22759200</object-id>; PubMed Central PMCID: PMCPMC3472020.</mixed-citation></ref>
<ref id="pmed.1002428.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bloom</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Trofe-Clark</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wiland</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Alloway</surname> <given-names>RR</given-names></name>. <article-title>A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients</article-title>. <source>Clin Transplant</source>. <year>2013</year>;<volume>27</volume>(<issue>6</issue>):<fpage>E685</fpage>–<lpage>93</lpage>. Epub 2013/10/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ctr.12256" xlink:type="simple">10.1111/ctr.12256</ext-link></comment> <object-id pub-id-type="pmid">24118450</object-id>.</mixed-citation></ref>
<ref id="pmed.1002428.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Macphee</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>Fredericks</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tai</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Syrris</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Carter</surname> <given-names>ND</given-names></name>, <name name-style="western"><surname>Johnston</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement</article-title>. <source>Transplantation</source>. <year>2002</year>;<volume>74</volume>(<issue>11</issue>):<fpage>1486</fpage>–<lpage>9</lpage>. Epub 2002/12/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/01.TP.0000045761.71385.9F" xlink:type="simple">10.1097/01.TP.0000045761.71385.9F</ext-link></comment> <object-id pub-id-type="pmid">12490779</object-id>.</mixed-citation></ref>
</ref-list>
</back>
</article>